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Abstract 
Evaluations of the Immunalysis enzyme linked immunosorbent assay (ELISA) and 
Immunalysis enzymatic assay for ethyl alcohol were undertaken to evaluate their 
suitability for screening drugs of abuse (namely amphetamine and 
methamphetamine) and alcohol in oral fluid samples collected with the Quantisal 
Collection Device. Multi-analyte controls were prepared for the drugs of abuse 
screen and diluted with Quantisal buffer prior to analysis to match the dilution in the 
Quantisal Oral Fluid Collection Device that was used to collect the samples. These 
samples were analysed over time to evaluate stability and case samples were 
analysed to evaluate sensitivity and specificity.  
Alcohol calibrators and controls were evaluated for linearity and stability before being 
applied to case samples to evaluate the sensitivity and specificity of the method.  
The amphetamine assay was found to be highly sensitive and specific. The 
methamphetamine assay was found to be highly specific but no positive samples 
were analysed so the sensitivity could not be evaluated. The multi-analyte controls 
were found to be stable over a fourteen month period. The Immunalysis ELISA 
assays were found to be suitable for screening oral fluid samples. 
The alcohol assay was found to be linear over the 0 ￿ 300mg/dL range and the 
calibrators and controls were found to be stable over time. The assay was found to 
be highly sensitive and specific and best suited to high throughput laboratories 
expecting mainly negative samples. However, it would not be cost effective for 
smaller laboratories or those expecting a high number of positives, where going 
straight to confirmation by head-space gas chromatography with flame ionisation 
detection would be recommended. Page 1 
 
1  Introduction 
1.1  Background 
Toxicology is the study of poisons and their effects, and has a wide range of 
applications in medicine, law and sport.   A poison is defined as any substance, 
which either formed in the body or taken into the body can cause an impairment of 
health (1, 2). This allows for the fact that almost all substances (including everyday 
essentials such as water and oxygen) can act as poisons and impair health if a high 
enough dose is taken (2). Other substances such as cyanide can be fatal even if 
only a small dose is received. Paracelsus reported this fact in the early 16
th century 
noting that even medicinal substances could be poisonous if a large quantity was 
consumed.  
￿Alle Dinge sind ein Gift und nichts ist ohne Gift, 
nur die Dosis bewirkt, da￿ ein Ding kein Gift ist.￿ 
￿Poison is in everything, and nothing is without poison.  
The dosage makes a thing not a poison.￿ 
Paracelsus, 1493-1541 
Quotation courtesy of The Handbook of Pesticide Toxicology: Principles (3) 
The dose required for toxic effects to be produced is known as the toxic dose but the 
actual quantity involved varies between individuals according to a number of factors. 
These include height, weight, sex, age, body water content, health, previous 
exposure to the drug, tolerance, mood at time the drugs were taken, effects of other 
drugs and the route of administration.  
Over the years, many matrices have been used to analyse for drugs and poisons in 
humans with tissues such as the liver, which have higher concentrations than the 
matrices commonly used today, being used for post mortem toxicology. Blood and 
urine are presently the most common matrices used in forensic toxicology for drugs 
of abuse testing. This is because these matrices are readily available and there is a 
lot of published information about typical concentrations of drugs found, thus aiding 
interpretation. Other ￿alternative￿ matrices which can be used in post mortem Page 2 
toxicology include the brain, liver, lung, muscle, stomach contents, bile, vitreous 
humour, hair, oral fluid, sweat and nail clippings. Over the last few decades, 
advances in technology has seen better sensitivity of instrumentation and this has 
brought hair and oral fluid testing, which typically have lower concentrations of drugs 
than the traditional matrices, to the front of the field. 
This project will look at the suitability of oral fluid as a testing matrix for the screening 
and subsequent confirmation of specifically alcohol and amphetamines. 
 
1.2  Oral Fluid 
1.2.1  Anatomy of Saliva Glands 
The secretion product of the head and mouth salivary glands is commonly known as 
saliva. Between half a litre and one and a half litres of saliva is produced daily from 
these glands (4-7). Saliva collected from the mouth also contains small amounts of 
gingival crevicular fluid, cellular debris and blood.  Saliva is composed of 99% water, 
0.3% protein (largely amylase) and 0.3% mucins (5, 8). Saliva glands comprise two 
regions, the acinar region which contains the cells capable of secretion and the 
ductal region lined with water impermeable cells that carry the secretions to the 
outlets in the mouth (8, 9).  
Saliva is produced from three main glands and many minor glands (7). Under resting 
conditions 70% is produced from the submandibular glands, 25% is produced by the 
parotid glands and the other 5% is produced from the sublingual glands and the 
other minor glands that produce saliva. When stimulated about 50% comes from the 
parotid glands (4, 7, 8). The main salivary glands are shown in Figure 1 courtesy of 
The Free Dictionary. Page 3 
 
Figure 1: The Saliva Glands courtesy of The Free Dictionary (10) 
 
Under resting conditions, saliva has a typical pH of 6.8 (typical range pH 5.6 ￿ 7.9) 
(8, 11). When stimulated, saliva is excreted faster and becomes more basic and 
approaches the pH of plasma (4, 8, 11). 
 In 1993, the New York Academy of Sciences meeting on saliva testing decided to 
differentiate between saliva taken from the mouth and that taken directly from the 
saliva glands. As the fluid in the mouth is a mixture of the excretion products from 
the various glands in the mouth and cellular debris it was decided that saliva should 
be used to describe the glandular secretions taken directly from the saliva glands 
and that oral fluid should be used to describe the fluid taken from the mouth by either 
expectoration or by placing absorbents in the mouth (5, 8, 11, 12). 
 
1.2.2  Advantages of Oral Fluid Testing 
The main advantage of oral fluid as a matrix for drug testing is that collection is 
simple and non-invasive and samples can be collected under observation. The 
collection of an oral fluid sample can be carried out by the individual themselves by 
swabbing the inside of their mouth with a cotton swab or by expectorating (spitting) 
into a sample vial. Suction and draining of oral fluid from the mouth have also been 
used to collect samples (8, 11, 12). This can be done quickly and on site, which is 
beneficial for both the individual concerned and the individual collecting the sample 
(13). In general, people do not like providing blood, urine or hair samples for analysis Page 4 
as they feel this is an invasion of their privacy (8). Urine samples can be easily 
adulterated or switched to avoid the detection of drugs, as the sample collection 
cannot be easily witnessed. This is not the case with oral fluid as there is a waiting 
time before sample collection in which any adulterants in the mouth will have been 
swallowed, diluted or expectorated (8). Also, the fact that sample collection is 
witnessed means the possibility of switching the sample to a sample known to be 
free from drugs is greatly reduced.  
Oral fluid provides information about recent drug use (i.e. drugs taken within a few 
hours of the sample being collected and up to 48 hours after use for some drugs) 
due to the short window of detection. As a consequence, oral fluid provides a good 
indication of the drugs that were present in the blood stream at the time of collection 
and therefore has the potential to provide information relating to the effects the 
individual was experiencing at the time of collection (8). 
Another advantage is that the concentration of drugs in oral fluid can be related to 
the concentration of drugs in plasma. Drugs found in oral fluid are typically the non-
ionised, unbound parent drug. Since it is the free lipophilic drug and drug metabolites 
that can cross cell membranes, such as the blood ￿ brain barrier, and cause 
physiological effects, free drug concentrations in plasma and in oral fluid can 
potentially be correlated with drug effects (5). Cone et al (14) found that for cocaine, 
the saliva concentrations correlated well with effects. In a separate study, Cone et al 
(15) stated that amphetamine in oral fluid parallels the plasma drug concentration. In 
contrast, many papers state that there is no correlation between oral fluid and 
plasma drug concentrations. Schepers et al (16) found a poor correlation between 
the oral fluid and plasma concentrations for amphetamine and methamphetamine. 
The results supported those from an earlier study by Cook et al (17). In 2007, Willie 
et al (18) carried out a multi ￿ drug study on oral fluid: blood ratios from drivers 
suspected of driving under the influence of drugs and found the ratios to be highly 
variable. 
 
1.2.3  Disadvantages of Oral Fluid Testing 
As oral fluid is a biological fluid, it has the potential to transmit infectious diseases. 
Thus samples need to be handled with care like other biological fluids such as blood Page 5 
and urine. Saliva production is reduced by some drugs, both prescription drugs (such 
as amitryptaline and paracetamol) and illicit drugs (such as amphetamine), drugs 
which block the central nervous system, and also by some medical conditions, 
including stress and diabetes (5, 7, 8, 11).This can make collection of oral fluid 
samples from individuals who fall into these categories difficult. There are also some 
individuals who are repulsed by spitting and thus rules out the use of expectoration 
methods for the collection of oral fluid. 
Although this is also classed as an advantage, another drawback with oral fluid 
testing is the short window of detection (8). Drugs with short half lives or those which 
are rapidly metabolised will not be detectable in oral fluid for a long period of time, as 
it is generally the parent drug that is found in oral fluid. As a result, in cases of those 
suspected of being under the influence of drugs it is vital that the oral fluid sample is 
collected as soon as possible to maximise the chance of detection. The generally 
accepted window of detection of oral fluid is from the time of administration to 
approximately four half lives after it enters the body (5). The half-life of a drug is the 
time taken for its concentration to decrease by a half. 
One of the biggest drawbacks with oral fluid testing is the small volume of sample 
collected (8). Many collection devices will only allow approximately 1mL of sample to 
be collected which, if many analyses are required, can present a problem. Many 
collection devices also dilute this 1mL of sample with buffer which can present a 
problem if the drugs are present at a low concentration, as it may be approaching the 
limit of detection of the analytical instrumentation. This problem was recently 
highlighted in a study by Gjerde et al, who carried out a large scale drug and alcohol 
study in Norway using the Statsure oral fluid collection device (19). This device used 
a collection pad to collect (up to) 1mL of oral fluid and diluted it with 1mL buffer. The 
authors reported that they were unable to recover 1mL of the oral fluid/buffer mixture 
meaning in most cases they had less than 1mL of sample to analyse (19).  
Another disadvantage relates to recent administration of a drug in oral form as 
residue from smoking or small fragments of the drug may remain in the mouth and 
as such will contaminate the oral fluid sample and give a much higher concentration 
of the drug than is actually present (11). 
 Page 6 
1.2.4  Applications of Oral Fluid Testing 
With drug testing becoming more widespread, companies such as those involved in 
drug  maintenance  programs,  many  private  companies  who  offer  drug  testing  for 
employers and the police (roadside and as part of the drug interventions program 
(DIP)), have been looking to move towards oral fluid testing as a method for drug 
testing  as  it  is  easier  to  collect  than  other  matrices.  The  police  for  example  can 
collect an oral fluid sample at the roadside rather than having to take the suspect to 
the station to provide a blood or urine sample which wastes time and money. The 
DIP programme tests those arrested for certain offences and aims to identify those 
taking drugs and giving them the option of deferring a prison sentence by enrolling 
them in drug treatment programmes. The test results from the DIP programme are 
not  used  in  court  against  the  suspect.  As  part  of  health  and  safety  regulations 
employers are able to test employees for the presence of alcohol or drugs only if 
consent  is  given  and there  is  a  genuine  reason for  the  test  (20).  Employers  are 
required to have a policy on drug and alcohol testing if they wish to carry out such 
tests. Not all companies have such a policy in place, but areas such as the transport 
and manufacturing sectors, where intoxication could endanger the lives of others, 
are most likely to have one in place. 
While a policy on workplace drug testing or consent is required for drug testing in 
most cases, it is a legal requirement in certain areas, such as the public transport 
industry. The Transport and Works Act 1992 (21) states that it is an offence for 
anyone working on public transport systems to be intoxicated while at work. 
As a result of the current recession, many companies which have not had a legal 
requirement to carry out workplace testing have started to test employees in an effort 
to dismiss them from their job without redundancy pay in a bid to save costs (22). 
Many people argue that an employee￿s human rights to privacy may be breached if 
testing is carried out using urine and hair, as they have longer windows of detection 
and as such do not reflect what, if any, effects the person is currently experiencing 
whilst at work. The longer windows of detection from these matrices could detect any 
recreational  use  of  drugs  out-with  working  hours  that  can  be  argued,  are  not 
affecting the person during work hours.  Page 7 
Drug maintenance programmes are used to monitor a person￿s abstinence from 
drugs. This may be for many reasons with child custody cases and conditions of bail 
being amongst the most common reasons. Drug maintenance programmes are also 
used to monitor those on the methadone programme to ensure that they are not 
continuing to abuse heroin while on methadone and to ensure that they are indeed 
taking their methadone and not selling it to provide money for other drug habits. 
The police in England and Wales also use oral fluid drug testing as a way of getting 
drug users who have been arrested for trigger crimes into treatment. Tests are 
routinely carried out on those who are arrested for petty crimes such as burglary or 
theft as part of the drug interventions programme (DIP) (23). This initiative aims to 
reduce crime carried out by drug abusers by getting them into treatment and the 
indications are that it has been working with a report published in November 2007 
indicating a 26% reduction in crime by those entering DIP (24). 
To test for alcohol intoxication at the roadside, the police use a hand-held 
breathalyzer, however there is currently no equivalent hand-held device approved to 
test for drug use at the roadside. Several collection devices have been tested over 
the years but as yet none has been deemed acceptable for roadside testing (11). 
The preliminary impairment test (PIT) is used to determine if a person is unfit to drive 
through drug intoxication and involves a series of simple tests and the measurement 
of pupil size. Technology is constantly evolving and in 2008 a British-based company 
announced they would be releasing a new handheld oral fluid drug testing device 
(25). The device will be unveiled in November 2010 and will undergo performance 
evaluation tests before being made commercially available but the manufacturers 
hope that the device will meet any criteria set out by the British government for 
roadside drug testing devices (26). The North Review, published by the Department 
of Transport in June 2010, states that the government is looking to implement a 
device that can detect drugs in oral fluid (27).  British police were given the power to 
carry out preliminary impairment tests on drivers suspected of using drugs in 2003, 
but as yet no suitable device for such a test exists. Section 6C of the Railways and 
Transport Safety Act 2003 (28) states that: 
￿A preliminary drug test is a procedure by which a specimen of sweat or saliva is￿ 
(a) obtained, and Page 8 
(b) used for the purpose of obtaining, by means of a device of a type approved by 
the Secretary of State, an indication whether the person to whom the test is 
administered has a drug in his body.￿ 
The Home Office Scientific Development Branch stated that ￿there is currently no 
type approval specification for roadside screening devices to detect drugs and so 
they cannot be used for enforcement purposes￿ and that they were working with 
external agencies on the specification and design of a suitable device (29). They 
went on to state that ￿it will be a couple of years before our multi-drug device is 
available and type-approved for use as the scientific development work behind it is 
highly complex￿ (29). 
 
1.3  Abuse of Drugs and Alcohol 
Drug  and  alcohol  abuse  is  a  growing  problem  in  the  United  Kingdom  (30,  31). 
Alcohol is the most commonly abused substance in the United Kingdom although 
drugs such as cannabis are also widely abused. According to the world drug report 
2009,  Scotland  was  the  amphetamine  abuse  capital  of  Europe  with  2.2%  of  the 
population  (2006  data)  abusing  amphetamines  and  amphetamine  type  stimulants 
(ATS)  (excluding  ecstasy)  (32).  Recently  published  data  in  the  world  drug  report 
2010  indicates  that  the  Czech  Republic  has  now  overtaken  Scotland  as  the 
amphetamine and amphetamine type stimulants (ATS) (excluding ecstasy) capital of 
Europe, as use in Scotland has dropped to 1.4% (2009 data) (33). Scotland also has 
the second highest rate of ecstasy abuse in Europe at 2.5% of the population (2009 
data), down from 3.2% in 2006, with only the Czech Republic having a higher rate at 
3.6%  (2008  data)  (3.5%  in  2004)  (32,  33).  Scotland  has  a  higher  rate  of 
amphetamine and ATS abuse than England and Wales (1.4% in Scotland compared 
to 1.0% in England and Wales (2009 data)) (33). Scotland also has a higher rate of 
ecstasy  abuse  than  England  and Wales  (2.5%  in  Scotland  compared  to  1.8%  in 
England and Wales (2009 data)) (33). 
Alcohol related deaths in the United Kingdom have doubled between 1991 and 2007 
according to the office for national statistics (31) as illustrated in Figure 2. 
In 2007 there were 1,399 deaths which listed alcohol as the underlying cause of 
death in Scotland with a further 966 listing alcohol as a contributory cause of death Page 9 
(34). 68.5% (959 of the 1,399 deaths) (34) of those who died as a result of an 
alcohol related illness were male. The Glasgow area had the highest death rate due 
to alcohol for both sexes (34) with the death rate for Scottish males double that of 
the rest of the United Kingdom (35). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Alcohol Related Death Rates by sex in the United Kingdom 1991 ￿ 2007 (31) 
 
Drug related deaths in Scotland have doubled since 1996 according to the General 
Register Office for Scotland (30) as illustrated in Figure 3.  
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Figure 3: Drug Related Deaths in Scotland 1996 ￿ 2009 (30) 
Figure 3 shows a fairly steady increase in drug related deaths since 1996. 
1.4  Screening Methods 
1.4.1  Drugs of Abuse 
Enzyme Linked ImmunoSorbent Assay (ELISA) is one of the most common 
screening techniques for drugs of abuse and is the screening method chosen for this 
project. Using an enzymatic method, such as ELISA to screen samples for drugs of 
abuse is a quick and relatively cheap method to eliminate negative samples from the 
more expensive and time consuming confirmatory tests (30, 31).  
ELISA works by having microplate wells coated with an antibody specific to the drug 
that is being looked for. The sample is added along with an enzyme labelled drug. 
The samples are incubated in the dark for a set period of time. The drug and enzyme 
labelled drug compete for binding sites on the antibody during the incubation period.  
The enzyme conjugates typically contain azide free preservatives as the presence of 
azides may interfere with the antigen ￿ antibody interactions and produce erroneous 
results. The plates are washed several times with water to remove any unbound 
materials and a substrate is added which allows a colour to develop in proportion to Page 11 
the amount of enzyme present (and inversely proportional to the concentration of 
drug in the sample well). The samples are incubated for a set period of time in the 
dark. After this incubation period, a stop solution (typically an acid) is added to 
destroy any unbound substrate and prevent further reaction. The colour of the 
solution is changed by the addition of the stop solution. The absorbance of the plates 
is then read. The process taking place in the wells is shown in Figure 4. 
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Figure 4: Principle of ELISA Courtesy of Pharmaceutical Press (36) 
 
1.4.2  Alcohol 
The Immunalysis Corporation (Pomona, CA) oral fluid alcohol assay works on the 
basis of alcohol dehydrogenase￿s (ADH) high affinity for reaction with ethanol in the 
presence of nicotinamide adenine dinucleotide (NAD) as shown in the equation 
below.  Page 13 
CH3CH2OH + NAD 
ADH
CH3CHO + NADH .......... Equation 1 
 
This simple method works by adding buffer and an enzyme which contains NAD and 
ADH to the sample and incubating in the dark for a set period of time. During this 
time, a colour develops in the wells. The absorbance of the plates is read following 
the incubation.  
 
1.4.3  Other Screening Methods 
A number of other screening methods are available with hand-held screening 
devices becoming popular with the police. Laboratory based techniques such as 
radioimmunoassay (RIA) (which has now been replaced by ELISA) (36) and liquid 
chromatography ￿ mass spectrometry ￿ mass spectrometry (LC-MS-MS) can also 
be used. LC-MS-MS appears to be the laboratory based screening method of the 
future as it offers the advantage over current screening methods by being able to 
identify specific drugs rather than just the drug group (37). It can also analyse for 
several hundred drugs in a single analysis (38). This technique can also be used 
semi-quantitatively which is advantageous if only a limited sample is available for 
analysis. It would also allow for any sample which may require a dilution prior to 
analysis to be identified at the screening stage, thus speeds up the confirmation step 
and saves wasting sample by extracting an undiluted sample when the drug will be 
off scale. The disadvantage of this technique is the cost and run time as multiple 
drug standards would be needed and a lot of validation work to set up the method for 
all of the analytes each particular laboratory is interested in.  
 
1.5  Confirmatory Methods 
1.5.1  Drugs of Abuse (Amphetamines) 
For this project, the presence of amphetamines in oral fluid was confirmed by gas 
chromatography mass spectrometry (GC-MS) following solid phase extraction (SPE) 
to remove the bulk of the impurities in the sample. Liquid chromatography mass 
spectrometry (LC-MS) is also frequently used to confirm the presence of 
amphetamines.  SPE is an extraction technique used to remove impurities from Page 14 
samples to stop them interfering with the chromatography on the instrument. 
Cartridges have a silica based packing material and the analytes of interest bind to it 
allowing the impurities to be washed out. The analytes of interest are then selectively 
eluted without the impurities. In the case of amphetamines the samples were 
derivatised (in this instance, with pentafluoropropionic anhydride (PFPA)) to improve 
the chromatography. The internal standards, used to quantify the drug 
concentrations, were deuterated analogues of each of the analytes of interest. 
Deuterated standards will have similar retention times as the standards themselves 
and allows for easier identification.  
 
1.5.2  Alcohol 
The presence of alcohol in oral fluid samples was confirmed by using headspace gas 
chromatography with a flame ionisation detector (GC-FID). For this project, the 
standards and controls were diluted with Quantisal buffer (one part sample, three 
parts buffer) to match the dilution in the oral fluid collection device.  A semi-automatic 
diluter was used to dilute the standards, controls and case samples with internal 
standard in clearly labelled headspace vials. All samples were analysed in duplicate. 
The vials were capped and placed in the carousel for analysis by headspace GC-
FID.  
 
1.6  Quality Control 
Although there is no formal requirement for drug testing laboratories in the United 
Kingdom to have accreditation to the international testing standard, ISO/IEC 17025, 
many laboratories that carry out the testing do have this accreditation, however, only 
a limited number have accreditation for oral fluid testing. As part of quality control 
measures,  there  are  various  proficiency  testing  schemes  in  operation  in  the  UK 
which accredited laboratories must participate in. However, these generally focus on 
the traditional matrices used in forensic toxicology such as blood and urine. As part 
of  the  proficiency  testing  scheme,  spiked  samples  are  sent  to  the  accredited 
laboratories  to  ensure  that  they  are  correctly  identifying  the  drugs  present  and 
accurately quantifying the concentrations in the sample. The concentration of the 
drugs  in  the  sample  is  not  given  to  the  testing  laboratories  until  after  they  have Page 15 
submitted  their  results  for  the  samples.  Samples  similar  to  this  are  commercially 
available  as  external  quality  controls  (EQC￿s)  but  these  samples  detail  the 
concentrations of the drugs present. At present, the EQC￿s are widely available for 
traditional  matrices  such  as  blood  and  urine  with  only  a  limited  number  being 
available  for  other  matrices,  such  as  oral  fluid,  and  thus  making  internal  quality 
controls (IQC￿s) very important in oral fluid testing. IQC￿s are control samples for the 
desired analytes that are prepared in-house to a known concentration and serve the 
same  purpose  as  the  EQC￿s.  In  order  to  gain  accreditation  to  ISO/IEC  17025, 
laboratories  must  meet  certain  requirements.  These  include  the  validation  of 
methods to ensure they are robust and fit for purpose, in addition to having standard 
operating procedures for all aspects of the testing process. A quality control system 
should  be  implemented  and  as  there  are  currently  no  external  quality  control 
schemes  available  for  oral  fluid,  the  quality  control  samples  must  therefore  be 
prepared  in-house.  The  United  Kingdom  National  External  Quality  Assessment 
Service (UKNEQAS) has a proficiency testing scheme that is currently being piloted 
for oral fluid testing but this is only at the developmental stage and has not been fully 
rolled out as yet. Schewart style quality control charts will be used to monitor the 
results  of the IQC￿s and EQC￿s.  
 
1.7  Quantisal Oral Fluid Collection Device 
The Quantisal oral fluid collection device was used to collect oral fluid samples for 
this project. The device has a pad with a volume adequacy indicator that turns blue 
when 1mL of oral fluid has been collected. The pad is then stored in 3mL of 
Quantisal buffer to give a total volume of 4mL. Filters can be used to squeeze the 
fluid out of the pad and allow the oral fluid/buffer mixture to be transferred to labelled 
vials prior to analysis. A study by Langel et al showed the Quantisal device had 
recoveries in excess of 80% for amphetamine, 3,4-
methylenedioxymethamphetamine (MDMA) and ethanol (39).  
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1.8  Aims and Objectives 
The aims of this project were to evaluate a commercially available ELISA assay for 
drugs of abuse, in particular, amphetamine and methamphetamine in oral fluid and 
to evaluate a commercially available enzymatic assay for ethanol in oral fluid. 
 
To evaluate the ELISA assay, multi-analyte controls were prepared and analysed 
over time to evaluate the stability of the controls and assess the suitability of the 
assays. To make the method more time and cost effective, the oral fluid samples 
were evaluated using the same ELISA method that is presently used in-house for 
other matrices (e.g. blood and urine) to allow oral fluid samples to be screened within 
the same batch as other matrices. The method was then applied to case samples 
collected with a commercially available oral fluid collection device and any 
amphetamine or methamphetamine positives will be confirmed using the in-house 
confirmation method of analysis by gas chromatography mass spectrometry (GC-
MS). Some negative samples were also confirmed to allow the sensitivity and 
specificity of the assay to be evaluated. Confirmations for other drug groups were not 
carried out during this project as there is not a validated in-house method for these 
drugs in oral fluid. 
To evaluate the enzymatic assay for ethanol in oral fluid, ethanol controls were 
prepared and analysed over time to evaluate the stability of the controls and assess 
the suitability of the assay. The method was then applied to case samples collected 
with a commercially available oral fluid collection device and any positives confirmed 
for alcohol using the in-house confirmation method of analysis by headspace gas 
chromatography flame ionisation detector (headspace GC-FID). Some negative 
samples were also confirmed to allow the sensitivity and specificity of the assay to 
be evaluated. 
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2  Evaluation of Multi-Analyte Oral Fluid Controls Using 
Immunalysis ELISA 
2.1  Materials and Reagents 
The following materials and reagents were used in this project. 
 
2.1.1  Enzyme Linked Immunosorbent Assay (ELISA) Test Kits 
Drugs of abuse testing kits for each of the drugs of interest were manufactured by 
Immunalysis Corporation (Pomona, CA) and purchased from their UK distribution 
company, Agriyork 400 Ltd (Pocklington, UK). The product code for each kit is 
detailed in Table 1. Each kit contained all the necessary reagents for the analysis, 
including an enzyme conjugate, a substrate solution and a stop solution. The 
substrate solution for all of the assays was 3, 3￿, 5, 5￿ tetramethylbenzidine (TMB) 
and urea peroxidase in buffer. The stop solution (1M hydrochloric acid) was the 
same for all assays. The enzyme conjugate for each assay is different and detailed 
in Table 1. The manufacturer￿s specification for each assay is given in Appendix 2 ￿ 
ELISA Assay Specification. 
 The calibrators were diluted with 100mM phosphate buffer solution (product code: 
PBS-1000) and Quantisal dilution buffer (product code: EXTBUF-1000) was used to 
dilute oral fluid controls. These buffers were also manufactured by Immunalysis 
Corporation (Pomona, CA) and purchased from their UK distribution company, 
Agriyork 400 Ltd (Pocklington, UK). The assays and buffers were stored at or below 
8￿C in the refrigerator. 
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Table 1: Product Codes and Enzyme Conjugates for ELISA Kits 
Drug Group  Product Code  Enzyme Conjugate* 
Amphetamine  209-0480  S-(+)-amphetamine 
Benzodiazepines  214-0480 
Benzodiazepine 
derivative 
Buprenorphine  236-0480 
Buprenorphine 
derivative 
Cannabinoids  205-0480 
THC-COOH 
derivative** 
Cocaine  206-0480 
Benzoylecgonine 
derivative 
Methadone  232-0480  Methadone derivative 
Methamphetamine  211-0480 
S-(+)-
methamphetamine 
Opiates  207-0480  Morphine derivative 
* Enzyme conjugates are labelled with horseradish peroxidase in a buffered, protein solution with 
stabilizers at pH 7.6 and contain azide free preservatives. The solutions are dyed pink for clarity. 
** The cannabinoid enzyme conjugate (11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH)) 
is buffered at pH 8.5. 
 
2.1.2  Drug Standards 
2.1.2.1  Drug Standards for ELISA 
The drug standards used for this project were manufactured by Cerilliant (Round 
Rock, TX) and purchased from LGC Standards (Teddington, UK). The details of the 
drug standard including the concentration and product code are found in Table 2. 
Certificates of analysis were provided with each drug standard. 
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Table 2: Drug Standards for ELISA 
Drug Standard  Concentration*  Product Code 
S-(+)-Amphetamine  1mg/mL  A-008 
Oxazepam  1mg/mL  O-902 
Buprenorphine  0.1mg/mL  B-902 
(-)-11-nor-9-carboxy-
delta9-THC 
0.1mg/mL  T-018 
Benzoylecgonine  0.1mg/mL  B-007 
(+/-)-Methadone  0.1mg/mL  M-019 
S-(+)-Methamphetamine  1mg/mL  M-020 
Morphine  0.1mg/mL  M-030 
* All drugs come in sealed vials at the stated concentration in 1mL of methanol. 
 
2.1.2.2  Drug Standards for GC-MS 
The drug standards used for this project were manufactured by Cerilliant (Round 
Rock, TX) and purchased from LGC Standards (Teddington, UK). The details of the 
drug standard including the concentration and product code are found in Table 3. 
Certificates of analysis were provided with each drug standard. 
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Table 3: Drug Standards for Amphetamine Confirmations 
Drug Standard  Concentration*  Product Code 
(–)-Amphetamine  1mg/mL  A-007 
(–)-Methamphetamine  1mg/mL  M-009 
(–)-MDA  1mg/mL  M-012 
(–)-MDMA  1mg/mL  M-013 
(–)-MDEA  1mg/mL  M-065 
* All drugs come in sealed vials at the stated concentration in 1mL of methanol. 
 
2.1.2.3  Internal Standards for Amphetamine Confirmations 
The deuterated drug standards used for this project were manufactured by Cerilliant 
(Round Rock, TX) and purchased from LGC Standards (Teddington, UK). The 
details of the deuterated drug standard including the concentration and product code 
are found in Table 4. Certificates of analysis were provided with each drug standard. 
Table 4: Internal Standards for Amphetamine Confirmations 
Drug Standard  Concentration*  Product Code 
(–)-Amphetamine-d11  100￿g/mL  A-016 
(–)-Methamphetamine-d14  100￿g/mL  M-092 
(–)-MDA-d5  100￿g/mL  M-010 
(–)-MDMA-d5  100￿g/mL  M-011 
(–)-MDEA-d6  100￿g/mL  M-081 
* All drugs come in sealed vials at the stated concentration in 1mL of methanol. 
 
2.1.3  Collection of Blank Oral Fluid 
As commercially available collection devices dilute the sample in differing volumes of 
buffer, it was decided to collect blank oral fluid by expectoration, as neat oral fluid 
would allow the flexibility of diluting samples by an appropriate factor at a later stage Page 21 
to match the dilution factor in the collection device of the sample in question should 
the sample be collected with a different collection device. Neat oral fluid was 
collected from a single donor who had not taken any of the drugs included in the 
analysis or those closely related to them prior to sample collection. Collection of oral 
fluid was carried out in one day by expectorating approximately 300mL into a beaker. 
The oral fluid was transferred to a large storage bottle and stored in the freezer until 
required.  
 
2.1.4  Preparation of Calibrators 
2.1.4.1  Preparation of Calibrators for ELISA 
As the in-house calibrators for this assay were also used for the routine blood and 
urine analysis which was accredited to ISO/IEC 17025, the calibrators were prepared 
by a member of technical staff to comply with the accreditation. The calibrators were 
prepared in the following way:  The levels were prepared from stock solutions of the 
drugs at a higher concentration than required and diluted to the required 
concentration with 25mL of water. The concentration of each drug in the four levels 
used for the calibration is shown in Table 5. The calibrators were stored in amber 
bottles at or below 8￿C in the refrigerator. The calibrators were diluted with buffer 
prior to use. 
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Table 5: Preparation of ELISA Calibrators 
Calibrators (ng/mL) 
Drug 
Lv1  Lv2  Lv3  Lv4 
Cut-off (ng/mL) 
Amphetamine  0  25  100  500  25 
Benzodiazepines  0  10  60  300  10 
Buprenorphine  0  5  20  100  5 
Cannabinoids  0  2  10  50  2 
Cocaine  0  10  60  300  10 
Methadone  0  5  20  100  5 
Methamphetamine  0  25  100  500  25 
Opiates  0  10  60  300  10 
 
2.1.4.2  Preparation of Standards for Amphetamine Confirmations 
The mixed amphetamine standard was prepared by adding 1mL of each of the drug 
solutions detailed in Table 3 to a single 100mL volumetric flask and diluting to the 
mark with methanol. The solution was inverted several times to ensure the solution 
was thoroughly mixed and transferred to a labelled storage bottle. This is the stock 
solution and was stored in the freezer at or below -18
oC. To make the working 
solution, 1mL of the stock solution was added to a 10mL volumetric flask and it was 
made up to the mark with methanol. The solution was inverted several times to 
ensure the solution was thoroughly mixed and transferred to a labelled storage 
bottle. This is the working solution and was stored in the fridge between 3-8
oC. 
 
2.1.4.3  Preparation of Internal Standard for Amphetamine Confirmations 
To prepare the amphetamine internal standard, 1mL of each of the solutions detailed 
in Table 4 was added to a single 10mL volumetric flask and diluted to the mark with 
methanol. The solution was inverted several times to ensure the solution was 
thoroughly mixed and transferred to a labelled storage bottle. This is the internal 
standard stock solution and was stored in the freezer at or below -18
oC. To make the Page 23 
working solution, 1mL of the stock solution was added to a 10mL volumetric flask 
and it was made up to the mark with methanol. The solution was inverted several 
times to ensure the solution was thoroughly mixed and transferred to a labelled 
storage bottle. This is the working internal standard solution and was stored in the 
fridge between 3-8
oC. 
 
2.1.5  Preparation of Controls 
2.1.5.1  Preparation of Controls for ELISA 
A number of solutions were prepared containing the drugs of abuse at appropriate 
concentrations. 1mL of each drug solution was pipetted from the vial into the 
appropriate volumetric flask (in the case of oxazepam this was after a 1 in 10 
dilution) and made up to the mark with blank oral fluid. Some solutions had more 
than one drug present as the controls were to be prepared with the drugs at the 
same concentration. The concentration of the solutions prepared along with the 
volume of the spiked solution added to the controls is indicated in Table 6. The 
controls were then pipetted into clearly labelled small vials and stored in the freezer 
until required.  
Table 6: Preparation of in-house ELISA Controls 
Control (ng/mL)  Spike Volume 
(￿L)  Drug Standard (Concentration) 
Working 
Solution 
(￿g/mL) 
Cut-off 
(ng/mL) 
- 50%  + 50%  - 50%  + 50% 
S-(+)-Amphetamine (1mg/mL) 
S-(+)-Methamphetamine (1mg/mL) 
100  25  13  38  13  38 
Oxazepam (1mg/mL)* 
Benzoylecgonine (100￿g/mL) 
Morphine (100￿g/mL) 
10  10  5  15  50  150 
+/- Methadone (100￿g/mL) 
Buprenorphine (100￿g/mL) 
10  5  3  8  30  80 
THC-COOH (100￿g/mL)  10  2  1  3  10  30 
* A one in ten dilution was required for oxazepam prior to making the mixed solution with 
benzoylecgonine and morphine. Page 24 
Amphetamine and methamphetamine formed one of the drug mixtures, oxazepam, 
morphine and benzoylecgonine formed another and methadone and buprenorphine 
formed the third. The cannabis solution was not part of a mixed drug solution. 
 
2.1.5.2  Preparation of Controls for Amphetamine Confirmations 
A separate bottle of amphetamine stock solution (10￿g/mL) was prepared as 
described above and marked as for controls only. From this solution, 0.45mL is 
added to a 100mL volumetric flask and made up to the mark with blank oral fluid. 
This gives a control spiked at 45ng/mL. The solution was inverted several times to 
ensure it was thoroughly mixed and 1.2mL aliquots were transferred to screw cap 
vials which were labelled as amphetamine oral fluid controls and stored in the 
freezer until required. 
 
2.1.6  Equipment 
Samples were washed using an MRX plate washer and analysed using an MRX 
microplate reader using a 450nm filter, all of which were purchased from Dynex 
Technologies (Chantilly, VA). Revelation software version 4.25 was used to process 
the results. 
The pipettes used in this project were calibrated by the United Kingdom 
Accreditation Service (UKAS) to ISO/IEC 17025 standard. Standards were prepared 
in volumetric flasks provided by Fisherbrand (Leicestershire, UK).  
The samples were analysed by GC-MS using an Agilent 7890A gas chromatograph 
coupled to an Agilent 5975C mass spectrometer. The system was automated using 
an Agilent 7683B series auto-sampler and processed using MSD Chemstation 
software (version G1701EA E.02.00.493). The gas chromatograph was fitted with a 
DB-5MA + DG column (30m x 0.25mm x 0.25￿m). All GC-MS related components 
were purchased from Agilent Technologies (Berkshire, UK). 
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2.1.7  Case Samples 
Case samples for this project were provided from three sources. Quantum 
Diagnostics (Essex, UK) provided approximately 100 samples for this project. The 
Centre for Drug Misuse Research based at the University of Glasgow (Glasgow, UK) 
provided approximately 210 samples for this project. Nine further samples were 
analysed as part of the United Kingdom National External Quality Assessment 
Service (UKNEQAS) proficiency testing scheme for oral fluid. 
 
2.2  Methods 
2.2.1  Method of Analysis (ELISA) 
The flowchart below shows the method for the diluted oral fluid controls which were 
generally used. An initial comparison of neat controls was done and the oral fluid 
QC￿s were not diluted with 750￿L Quantisal buffer. The method used for ELISA is 
detailed in Figure 5. 
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Allow all materials, 
reagents and samples 
to come to room 
temperature. 
 
Record the temperature of 
the room. 
  Test washer and record 
pass or fail in 
maintenance log. 
       
 
Add 500￿L of samples 
to labelled culture 
tubes. 
  Add 250￿L calibrators and 
QC￿s to labelled culture 
tubes. 
  Label culture tubes for 
calibrators, QC￿s and 
samples. 
 
       
Add 1mL PBS buffer 
to calibrators. 
  Add 0.75mL Quantisal 
buffer to oral fluid QC￿s 
(and any undiluted 
samples). 
 
Vortex mix all culture 
tubes. 
       
 
Add 100￿L of enzyme 
conjugate (specific to 
assay) to each well. 
  Pipette 10￿L of each 
calibrator, QC and sample 
into wells in duplicate. 
  Label appropriate 
number of strips for 
each drug group. 
 
       
Incubate plates at 
room temperature in 
the dark for one hour. 
  Wash plates six times with 
water using a plate washer. 
  Add 100￿L of substrate 
solution to each well 
(not assay specific). 
       
 
Add 100￿L stop 
solution to each well. 
  While incubating, prepare 
plate reader by creating 
sample ID list. 
  Incubate plates at room 
temperature in the dark 
for 30 minutes. 
 
     
Read plates at 450nm 
using the reader. Print 
and save results. 
 
Process results.   
       
 
Figure 5: Flowchart Showing the ELISA Method Page 27 
 
 
2.2.2  Data Processing 
To process the results, the percentage binding of the calibrators and controls were 
calculated. The absorbance for the first positive calibrator was chosen as the cut-off 
value for the assay. The binding of the blank calibrator and the blank control were 
assumed to have 100% binding. The ratio of the absorbance of the other calibrators 
to the absorbance of the blank calibrator allows the percentage binding to be 
calculated for the calibrators and in a similar fashion the ratio of the positive controls 
absorbance to the blank control allows the percentage binding for the controls to be 
calculated. The formula used to calculate the percentage binding is given below: 
 
Percentage binding = (B/B0) x 100.......... Equation 2 
 
Where B is the mean absorbance of calibrator or control and B0 is the mean 
absorbance of the blank calibrator or blank control. 
Using a different blank for the controls and calibrators allows any matrix effects on 
the absorbance to be considered. Using the percentage binding is a good way to 
normalize the results as the absorbance recorded will vary from day to day due to 
different assays and length of time incubated. The ratio between the levels should 
remain relatively constant and this will be monitored using a QC chart for each of the 
assays investigated. The results were used to construct Schewart style control 
charts as detailed in section 2.3.3. 
As the samples are analysed in duplicate, the mean absorbance value for the 
sample is used for the calculation outlined above. The variation between these 
duplicate results is also monitored and if it is out with an acceptable level then the 
outlier can be discarded and the absorbance value from the other well used for the 
percentage binding calculation. The acceptable level of variation between the 
duplicate calibrators is 15% and between duplicate samples is 20%.   
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2.2.3  Method of Analysis (Confirmations) 
Amphetamines are extracted by a solid phase extraction method. The extraction 
procedure for amphetamines in oral fluid is shown in Figure 6. A worksheet for the 
extraction procedure utilised was required to be filled in as part of the accreditation 
and is shown in Appendix 1. 
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Remove two controls 
from freezer and 
samples from the 
fridge. 
  Label test tubes, SPE 
cartridges, elution vials and 
injection vials. 
  Add standard (1￿g/mL) 
to standard test tubes. 
See Table 7. 
       
 
Add 1mL blank oral 
fluid to standard and 
blank test tubes. 
  Add 3mL phosphate buffer 
(0.1M, pH6) to all test 
tubes. 
  Add 50￿L internal 
standard (1￿g/mL) to all 
test tubes. 
 
       
Add 1mL of control to 
each control test tube. 
  Add 0.5mL of sample to the 
appropriately labelled test 
tube. 
  Vortex and centrifuge 
all test tubes for ten 
minutes. 
       
 
Wash columns. 
1 x 3mL water 
1 x 1M acetic acid 
1 x 3mL methanol 
 
Apply samples to 
appropriately labelled 
columns. 
  Condition SPE 
cartridges.  
1 x 3mL methanol 
1 x 3mL water 
1 x 1mL buffer 
 
       
Dry columns under full 
vacuum for five 
minutes. 
  Wipe needles dry and place 
labelled elution vials under 
needles.   
  Elute with 3mL 
DCM/IPA/NH3 (78:20:2 
v/v/v). 
       
 
Derivatise with 50￿L 
PFPA:EtOAc (2:1 v/v) 
at 60
oC for 20 minutes 
in capped vials. 
  Evaporate to dryness under 
nitrogen at ROOM 
temperature. 
  Add 100￿L tartaric acid 
(1mg/mL). Vortex 
samples. 
 
       
Allow to cool and 
evaporate to dryness 
under nitrogen at 
ROOM temperature. 
 
Reconstitute in 50￿L ethyl 
acetate. 
  Transfer to labelled 
injection vials with low 
sample volume inserts. 
         
Figure 6: Flowchart for Confirmation of Amphetamines in Oral Fluid Page 30 
 
The standard concentrations used are shown in Table 7. 
Table 7: Volume of Mixed Amphetamine Standard for Amphetamines Extraction 
Standard Concentration 
(ng/mL) 
Volume of mixed 
amphetamines standard 
(1￿g/mL) 
Volume of mixed 
amphetamines internal 
standard (1￿g/mL) 
0  0￿L  50￿L 
5  5￿L  50￿L 
10  10￿L  50￿L 
25  25￿L  50￿L 
50  50￿L  50￿L 
100  100￿L  50￿L 
200  200￿L  50￿L 
 
2.2.4  GC-MS Conditions 
The GC was operated in splitless mode, with 1￿L of sample being injected by the 
auto-sampler. The injection port was heated to 225
oC. The oven temperature was 
initially set at 55
oC and held for two minutes. The temperature was then ramped at 
20
oC/min to 200
oC and then at 10
oC/min to 250
oC and on to 300
oC at 25
oC/min. The 
final temperature of 300
oC was held for two minutes. Helium (99.99% purity) was 
used as the carrier gas at a flow rate of 1mL/min. The sample was transferred via a 
transfer line heated to 250
oC to a 70eV electron impact (EI) ionisation source heated 
to 230
oC. The mass spectrometer was operated in the selected ion monitoring (SIM) 
mode. The ions monitored are shown in Table 8. 
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Table 8: Ions Monitored in SIM Mode 
Drug  IS Ion 
Quantifying 
Ion 
Qualifying 
Ion 
Qualifying 
Ion 
Amphetamine  194  190  118  91 
Methamphetamine  211  204  160  118 
MDA  330  325  190  162 
MDMA  344  339  204  162 
MDEA  359  353  218  162 
 
 
2.2.5  Processing of Results 
MSD Chemstation software was used to process the data and calculated the ratio of 
the quantifier ion from the desired analytes to the quantifier ion from corresponding 
deuterated internal standard. The resulting calibration graphs gave linear responses 
for all analytes of interest over the calibration range of 5 ￿ 200ng/mL. The results 
from the controls were used to construct Schewart style control charts as detailed in 
section 2.3.3. 
 
2.3  Experimental Section 
2.3.1  Response of Calibrators 
To determine the suitability of the calibrators, a blank and three positive calibrators 
for each drug was evaluated as part of the ISO/IEC 17025 accreditation and was not 
repeated for this project. From this work, calibrators were prepared at the 
concentrations detailed in Table 5 above and a set of calibrators were run with each 
plate to ensure that each assay was acceptable and to determine the cut-off value 
for the assay on each separate run, as this was susceptible to change between lot 
numbers of assays and slightly different incubation times in each analysis. The Page 32 
responses for the assays of interest are detailed in the results section. The mixed 
drug calibrators were used for each drug group. 
 
2.3.2  Limit of Detection 
To determine the limit of detection of the assays, twelve replicates of the blank 
control were run in duplicate on one plate. The mean and standard deviation for 
these samples were calculated and the mean minus two times the standard 
deviation was calculated (as the blank for the ELISA assays is the highest value) to 
determine the limit of detection. This work was only carried out for the amphetamine 
and methamphetamine plates. 
 
2.3.3  Preparation of Shewart-Style Quality Control Charts 
The mean value for the control chart was determined by averaging the percentage 
binding values from the first positive calibrator over a period of ten runs. The data 
from these runs was also used to calculate the mean –2SD and the mean –3SD and 
these values are indicated on the appropriate charts. Control charts for both the 50% 
above and 50% below the cut-off controls were constructed in the same way to that 
of the cut-off control charts. The same procedure was followed for the preparation of 
control charts for the amphetamine confirmation method. 
Any subsequent sets of controls which were prepared were evaluated and if the 
results fell within the limits of the previous control, they were plotted on the previous 
control chart. If the values were out with the limits, a new control chart was 
constructed in the same way as the original charts. The results for the amphetamine 
and methamphetamine assays can be found in section 2.4.4. The charts for the 
other drugs can be found in Appendix 3 ￿ ELISA QC Charts. 
 
2.3.4  Criteria for Acceptability 
All results should fall within three standard deviations of the mean and ideally within 
two standard deviations of the mean. One control outwith the mean –2SD is 
acceptable provided the other is within that range. Trends of controls being higher or 
lower than ￿normal￿ may be observed due to small differences in the preperation of Page 33 
calibrators. When the controls are repeatedly falling out with the acceptable range it 
indicates that the controls are no longer stable for the drug group in question. 
 
2.3.5  Stability of Drugs in Oral Fluid 
To evaluate the stability of drugs in oral fluid the percentage binding of the controls 
were calculated as described above (in section 2.2.2) and plotted on a QC chart. The 
stability of the controls is monitored over time by monitoring any significant change in 
the percentage binding, as indicated on the QC chart by the points being out with the 
acceptable range of the mean –2SD. Over time, drugs will become unstable and 
start to break down resulting in an upward trend being observed in the QC charts. As 
multi-analyte controls were prepared, trends for other drugs groups were also 
monitored. The controls were stored in neat oral fluid, while case samples were 
diluted with buffer.  
 
2.3.6  Sensitivity and Specificity 
The sensitivity of the assay is defined as the efficiency of the assay in detecting 
positive samples and was calculated as follows and expressed as a percentage: 
Sensitivity = (TP/ (TP + FN)) *100 .......... Equation 3 
Where TP = True positives and FN = False negatives. 
The specificity of the assay is defined as the efficiency of the assay in detecting 
negative samples and was calculated as follows and expressed as a percentage: 
Specificity = (TN/ (TN + FP)) *100 .......... Equation 4 
Where TN = True negatives and FP = False positives. 
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2.4  Results and Discussion 
2.4.1  Calibration 
The calibration for the assays used for oral fluid analysis was calculated using 
revelation software. The software displayed an error message if the calibration was 
not acceptable. 
 
2.4.2  Limit of Detection 
The limit of detection for amphetamine and methamphetamine in diluted oral fluid 
using Immunalysis ELISA assays is shown in Table 9.  
 
The absorbance value for the limit of detection for amphetamine within this batch is 
1.706 which is much higher than the absorbance value of the cut off concentration 
from this batch (0.594), thus there is no problem with sensitivity for this assay. 
Similarly methamphetamine, which has an absorbance value of 1.264 for the limit of 
detection in this batch, is sufficiently sensitive as the LOD is much higher than the 
absorbance value at the cut-off concentration (0.557) from this batch. 
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Table 9: Limit of Detection Results 
Amphetamine  Methamphetamine 
Sample No:  Mean of duplicate 
absorbance values 
Mean of duplicate 
absorbance values 
1  1.896  1.347 
2  1.853  1.347 
3  1.933  1.295 
4  1.957  1.378 
5  1.912  1.440 
6  1.844  1.390 
7  1.917  1.317 
8  2.011  1.437 
9  1.792  1.485 
10  1.700  1.453 
11  1.791  1.448 
12  1.896  1.526 
Mean  1.875  1.405 
Standard Deviation (SD)  0.085  0.071 
2 x SD  0.169  0.141 
Mean ￿ 2SD  1.706  1.264 
%CV  4.5  5.0 
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2.4.3  Stability of Drugs in Neat Oral Fluid 
As the controls are being evaluated for a number of different drugs, the results for 
each drug will be shown in a table with a set of charts for one drug shown as an 
example.  
The mean value and the values for the mean –2SD and the mean –3SD for each 
drug are given in the table below. The figures shown were calculated from the results 
obtained from the first six runs using the controls.  
Table 10: Percentage Binding of Drugs of Abuse in Neat Oral Fluid at the Cut-off Concentration 
Drug  Mean-3SD  Mean-2SD  Cut-off Mean  Mean+2SD  Mean+3SD 
AMP  22.76  24.89  29.15  33.40  35.53 
BEN  49.96  54.06  62.26  70.47  74.57 
THC  89.29  90.92  94.19  97.46  99.10 
COC  64.03  67.09  73.19  79.30  82.35 
METH  63.89  67.18  73.75  80.33  83.62 
MAMP  35.86  37.22  39.94  42.65  44.01 
OP  7.21  19.84  45.11  70.38  83.01 
 
Table 11: Percentage Binding of Drugs of Abuse in Neat Oral Fluid at 50% Below the Cut-off 
Concentration 
Drug  Mean-3SD  Mean-2SD  -50% Mean  Mean+2SD  Mean+3SD 
AMP  8.26  9.43  11.78  14.13  15.31 
BEN  28.47  33.22  42.73  52.23  56.99 
THC  49.37  54.11  63.58  73.05  77.79 
COC  29.01  39.47  60.41  81.34  91.81 
METH  15.25  27.24  51.21  75.18  87.16 
MAMP  16.13  19.74  26.95  34.17  37.78 
OP  8.18  11.19  17.22  23.24  26.25 
 
Table 12: Percentage Binding of Drugs of Abuse in Neat Oral Fluid at 50% Above the Cut-off 
Concentration 
Drug  Mean-3SD  Mean-2SD  +50% Mean  Mean+2SD  Mean+3SD 
AMP  5.50  5.91  6.73  7.54  7.95 
BEN  17.25  21.17  29.00  36.83  40.75 
THC  41.41  45.81  54.59  63.38  67.77 
COC  25.20  31.42  43.86  56.31  62.53 
METH  8.32  17.26  35.14  53.01  61.95 
MAMP  11.39  14.25  19.96  25.68  28.54 
OP  7.18  8.37  10.75  13.12  14.31 
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As can be seen from the tables above, some drugs have a very narrow range of 
acceptability, from the mean minus three times the standard deviation to the mean 
plus three times the standard deviation, while others have a much larger range of 
acceptability. The percentage binding for the controls spiked at 50% below the cut-
off concentration are lower than the percentage binding at the cut-off concentration 
as the controls were undiluted whereas the calibrators are diluted in 1mL of buffer 
which results in the controls appearing to be at a higher concentration than they 
actually are.  
A sample set of charts at the cut-off value, 50% above and 50% below this value are 
shown below for amphetamine. The results are plotted against run number to allow 
any trends to be observed. The time period between the first and last run is 
approximately four months. 
 
The control chart for amphetamine at the cut-off concentration in neat oral fluid is 
shown in Figure 7. 
 
Figure 7: ELISA Control Chart for Amphetamines in Neat Oral Fluid at the Cut-off Concentration 
 
As can be expected, the results all fall within two standard deviations of the mean as 
the six results were used to calculate the limits of the chart.   Page 38 
The control chart for amphetamine at 50% below the cut-off concentration in neat 
oral fluid is shown in Figure 8. 
 
 
Figure 8: ELISA Control Chart for Amphetamines in Neat Oral Fluid at 50% Below the Cut-off 
Concentration 
As can be seen from the chart above, all but one sample fell within the mean –2SD 
range. All data points on the chart were used to calculate the limits. It is worth noting 
that for this particular control the range from minus three times the standard 
deviation to plus three times the standard deviation is rather small, only around eight 
percent, which means that a slight pipetting error or an innaccuracy in incubation 
time will make the control likely to fall out with the acceptable range. 
 
The control chart for amphetamine at 50% above the cut-off concentration in neat 
oral fluid is shown in Figure 9. Page 39 
 
Figure 9: ELISA Control Chart for Amphetamines in Neat Oral Fluid at 50% Above the Cut-off 
Concentration 
 
As can be seen from the chart above, all the results fall within the mean –2SD  
range. All data points on the chart were used to calculate the limits. It is worth noting 
that for this particular control the range from minus three times the standard 
deviation to plus three times the standard deviation is incredibly small, only around 
three percent, which means that a slight pipetting error or an innaccuracy in 
incubation time will make the control likely to fall out with the acceptable range. 
 
As the range for the neat oral fluid controls was so small it was decided that diluted 
controls would be used for the remainder of the project and thus no further data was 
collected for the neat oral fluid controls. 
 
2.4.4  Stability of Drugs in Diluted Oral Fluid 
As the controls are being evaluated for a number of different drugs, the results for 
each drug will be shown in a table with a set of charts for the main analytes of 
interest in this project, amphetamine and methamphetamine, being shown as an 
example. The charts for the other drugs can be found in Appendix 3 ￿ ELISA QC 
Charts. Page 40 
The mean value and the values for the mean plus and minus two and three times the 
standard deviation for each drug are given in the table below. The figures shown 
were calculated from the results obtained from the first ten runs using the controls.  
Table 13: Cut-off Concentration for Drugs of Abuse in Diluted Oral Fluid 
Drug  Mean-
3SD 
Mean-
2SD 
Cut-
off 
Mean 
Mean+2SD  Mean+3SD 
AMP  23.2  25.1  29.0  33.0  34.9 
BEN  49.1  54.0  63.8  73.7  78.6 
THC  87.6  89.8  94.3  98.7  100.9 
COC  60.0  63.9  71.5  79.2  83.0 
METH  54.0  59.9  71.8  83.6  89.5 
MAMP  36.0  37.2  39.8  42.3  43.6 
OP  11.3  23.2  47.0  70.8  82.7 
 
Table 14: 50% Below Cut-off Concentration for Drugs of Abuse in Diluted Oral Fluid 
Drug  Mean-
3SD 
Mean-
2SD 
-50% 
Mean  Mean+2SD  Mean+3SD 
AMP  18.1  22.7  31.9  41.1  45.7 
BEN  56.2  60.3  68.6  76.8  81.0 
THC  58.1  65.1  79.1  93.0  100.0 
COC  47.2  59.1  83.0  106.8  118.8 
METH  33.8  51.7  87.5  123.4  141.3 
MAMP  20.8  27.8  41.7  55.6  62.6 
OP  25.5  29.4  37.2  45.1  49.0 
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Table 15: 50% Above Cut-off Concentration for Drugs of Abuse in Diluted Oral Fluid 
Drug  Mean-
3SD 
Mean-
2SD 
+50% 
Mean  Mean+2SD  Mean+3SD 
AMP  11.0  13.5  18.3  23.2  25.7 
BEN  42.9  47.0  55.3  63.6  67.8 
THC  41.8  51.7  71.4  91.2  101.0 
COC  33.1  44.4  67.1  89.8  101.2 
METH  34.7  47.3  72.4  97.6  110.2 
MAMP  18.7  23.2  32.3  41.4  45.9 
OP  15.1  17.5  22.4  27.3  29.7 
 
The results above show that there is a larger range of acceptable values for the 
controls when diluted with Quantisal buffer. This improves the range for 
amphetamine from around 3% to around 12% for the 50% above the cut-off 
concentration which gives more flexibility for any marginal error during the analysis. 
However, for the same control, the range of acceptability for methadone has 
increased from around 35% to around 50%. This wide range means that if there is a 
problem with the stability of methadone then it may be more difficult to see as it may 
not be apparent as the results may still be within the acceptable range. The 
percentage binding for the controls spiked at 50% below the cut-off concentration are 
lower than the percentage binding at the cut-off concentration as the controls are 
diluted in 0.75mL of buffer whereas the calibrators are diluted in 1mL of buffer which 
results in the controls appearing to be at a higher concentration than they actually 
are. 
The data presented in the charts below spans a period of approximately 14 months, 
although the gap between analyses is not consistent as oral fluid samples were not 
arriving on a regular basis at the start of the project.  
 
2.4.4.1  Amphetamine 
The control chart for amphetamine at the cut-off concentration in diluted oral fluid is 
shown in Figure 10. Page 42 
 
Figure 10: Cut-off Concentration for Amphetamine in Diluted Oral Fluid 
 
The cut-off control chart for amphetamines in diluted oral fluid shows that for multiple 
different preparations of the calibrators, the percentage binding between the first 
positive calibrator and the negative calibrator remains fairly constant, with the 
majority of points falling within the acceptable range. A number of sets of calibrators 
(six) have been used while this QC chart has been in operation and none of them 
has deviated significantly from the mean. The cumulative mean (30 runs) for this 
chart (29.3%) is slightly higher than the mean (10 runs) displayed on the chart 
(29.0%) and represents a change of  0.9% from the originally calculated mean and 
confirms the consistency in the preparation of multiple calibrators used in this study. 
 
The control chart for amphetamine at 50% below the cut-off concentration in diluted 
oral fluid is shown in Figure 11. Page 43 
 
Figure 11: 50% Below Cut-off Concentration for Amphetamine in Diluted Oral Fluid 
 
The control chart for the control spiked at 50% below the cut-off level shows good 
stability for amphetamine over the course of the charts use, which was 
approximately fourteen months, with all but one value falling within the acceptable 
range. The cumulative mean (30 runs) for this chart (30.2%) is slightly lower than the 
mean (10 runs) displayed on the chart (31.9%) and represents a change of -5.5% 
from the originally calculated mean and provides evidence that there is no significant 
loss of amphetamine from the controls.  
 
The control chart for amphetamine at 50% above the cut-off concentration in diluted 
oral fluid is shown in Figure 12. Page 44 
 
Figure 12: 50% Above Cut-off Concentration for Amphetamine in Diluted Oral Fluid 
 
The control chart for the 50% above the cut-off value for amphetamine also shows 
good stability over time with almost all samples falling within the acceptable range. 
The cumulative mean (30 runs) for this chart (16.8%) is slightly lower than the mean 
(10 runs) displayed on the chart (18.3%) and represents a change of -8.3% from the 
originally calculated mean. While an 8.3% change in the mean value over the period 
of use appears to be large, it is only 1.5% lower than the original value but the 
percentage binding for this control was low and as such will give a higher percentage 
change in value. The change is small enough to show that the control is stable over 
time. 
 
The amphetamine cut-off and control charts all show good consistency over the 
fourteen month period that they have been in operation as evidenced by almost all of 
the points being within the acceptable range. The cut-off chart shows the most 
disagreement and this is likely to be due to experimental error in the multiple 
preparations of the calibrators that were in use throughout this project. This provides 
evidence that amphetamine controls are stable in neat oral fluid stored in a freezer 
and diluted prior to analysis for a period in excess of twelve months. 
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2.4.4.2  Methamphetamine 
The control chart for methamphetamine at the cut-off concentration in diluted oral 
fluid is shown in Figure 13. 
 
Figure 13: Cut-off Concentration for Methamphetamine in Diluted Oral Fluid 
 
For a period of time, the cut-off concentration has failed for methamphetamine. This 
is likely to be down to two contributing factors. The first could result from an error in 
the preparation of the calibrator as the values during this period were noticeably 
higher than those typically seen in this chart. This is highly likely as the calibrators 
used were those used for the routine ELISA screen and the calibrators were 
prepared by several different people during this period.  The second reason is the 
very low range of acceptability for this chart. Acceptable values must fall within a 
5.1% range, which contrasts sharply with the cut-off chart for some other drug 
groups where the acceptable range is greater than 20%. An upwards trend is 
observed at this point and that could indicate that the methamphetamine calibrator 
was starting to break down, although a new preparation of the calibrator was also 
giving high results. The cumulative mean (30 runs) for this chart (41.8%) is slightly 
higher than the mean (10 runs) displayed on the chart (39.8%) and represents a 
change of 5.2% from the originally calculated mean and shows that there is no 
substantial variation when preparing new calibrators.  Page 46 
The control chart for amphetamine at 50% below the cut-off concentration in diluted 
oral fluid is shown in Figure 14. 
 
Figure 14: 50% Below Cut-off Concentration for Methamphetamine in Diluted Oral Fluid 
 
The control chart for the control spiked at 50% below the cut-off level shows good 
stability for methamphetamine over a period of fourteen months with all values falling 
within the acceptable range. The cumulative mean (30 runs) for this chart (42.8%) is 
slightly higher than the mean (10 runs) displayed on the chart (41.7%) and 
represents a change of 2.6% from the originally calculated mean and provides 
evidence that there is no loss of methamphetamine from the controls whatsoever.  
 
The control chart for amphetamine at 50% above the cut-off concentration in diluted 
oral fluid is shown in Figure 15. Page 47 
 
Figure 15: 50% Above Cut-off Concentration for Methamphetamine in Diluted Oral Fluid 
 
The control chart for the control spiked at 50% above the cut-off level shows good 
stability for methamphetamine over a period of fourteen months with almost all 
values falling within the acceptable range. The cumulative mean (30 runs) for this 
chart (33.1%) is slightly higher than the mean (10 runs) displayed on the chart 
(32.3%) and represents a change of 2.4% from the originally calculated mean and 
provides evidence that there is no loss of methamphetamine from the controls over 
the time period studied.  
The methamphetamine cut-off and control charts all show good consistency over the 
fourteen month period that they have been in operation as evidenced by almost all of 
the points being within the acceptable range. This provides evidence that 
amphetamine controls are stable in neat oral fluid stored in a freezer and diluted 
prior to analysis for a period in excess of twelve months. 
 
2.4.5  Amphetamine and Methamphetamine ELISA Control Chart Conclusions 
The results from the control charts for amphetamine and methamphetamine indicate 
that controls prepared and stored in the manor used in this project would be suitable 
for use for a period in excess of one year after preparation, however, a longer study Page 48 
would be required to determine exactly how long the controls are stable for. Some 
other drugs are exhibiting an upward or downward trend in their control chart 
suggesting that they may no longer be stable, however, they are still within the 
acceptable range at present and the trend is mirrored in the cut-off chart which 
suggests that it may be more to do with a change in calibrator rather than a stability 
issue. The control charts for the other drugs are included for reference in Appendix 3 
￿ ELISA QC Charts. The cut-off charts however, show a different picture with the 
amphetamine control chart which has a wide range of acceptable values being 
perfectly acceptable but the methamphetamine chart which had a narrow range of 
acceptable values was out when there was a slight error in the preparation of the 
calibrators. Interestingly, if the cumulative data was used for methamphetamine then 
almost all results would be acceptable as the standard deviation is larger due to a 
higher number of different sets of calibrators being prepared. If the controls are 
found to be stable over a longer period of time then it would make sense to make a 
larger quantity of controls and collect more data for the construction of the control 
charts to give a more representative mean and standard deviation for the long term.   
The percentage change from the mean after ten runs to the mean after thirty is 
deceptively high for amphetamine and methamphetamine as they have low 
percentage binding values in comparison to the other drug groups in the controls. 
Increasing the number of runs to collate data for the cut-off charts would be an 
improvement to the current method as the calibrators are prepared far more 
frequently and by numerous different people, thus resulting in greater variation than 
the controls which are prepared far less frequently. Keeping the number of runs for 
the 50% above and below controls would be the best way forward as there should 
not be as much variation in these values. 
 
2.4.6  Amphetamine QC Charts for GC-MS 
Control charts were created for each of the five analytes in the amphetamine 
analysis. Only the control chart for amphetamine will be shown. The control charts 
for the other analytes can be found in Appendix 4 ￿ Confirmation QC Charts. The 
control chart for amphetamine is shown in Figure 16. Page 49 
 
Figure 16: Amphetamine Control Chart 
 
The control chart for amphetamine shows that the majority of samples fall within the 
acceptable range and that there is no downward trend indicating that there is no loss 
of analyte over time. None of the other control charts exhibited any loss of analyte 
over time.  
 
2.4.7  Case Samples 
2.4.7.1  Confirmed Samples 
A number of case samples (both positives and negatives) were confirmed for the 
presence of amphetamines by GC-MS. The results of the case samples are given in 
Table 16. The confirmation results in the table are split as the amphetamine ELISA 
plate screened for amphetamine and MDA while the methamphetamine ELISA plate 
screened for methamphetamine, MDMA and MDEA. 
 
 
 Page 50 
Table 16: Results from Amphetamine Confirmations 
Sample  Screening  Confirmations (results in ng/mL) 
Sample ID  AMP  MAMP  AMP  MDA  MAMP  MDMA  MDEA 
015070  N/A  N/A  Neg  Neg  Neg  Neg  Neg 
027660  Neg  Neg  Neg  Neg  Neg  Neg  Neg 
027713  Neg  Neg  Neg  Neg  Neg  Neg  Neg 
041616  Positive  Neg  58  Neg  Neg  Neg  Neg 
041669  Neg  Neg  Neg  Neg  Neg  Neg  Neg 
041670  Neg  Neg  Neg  Neg  Neg  Neg  Neg 
041676  Neg  Neg  Neg  Neg  Neg  Neg  Neg 
042532  Positive  Neg  Neg  Neg  Neg  Neg  Neg 
043746  Neg  Neg  Neg  Neg  Neg  Neg  Neg 
043839  Neg  Neg  <5  Neg  Neg  Neg  Neg 
043881  Neg  Neg  Neg  Neg  Neg  Neg  Neg 
043914  Neg  Neg  <5  Neg  Neg  Neg  Neg 
044102  Neg  Neg  15  Neg  Neg  Neg  Neg 
044116  Neg  Neg  Neg  Neg  Neg  Neg  Neg 
057429  Positive  Neg  142  Neg  Neg  Neg  Neg 
092020  Positive  Neg  281  Neg  Neg  Neg  Neg 
092045  Positive  Neg  30  Neg  Neg  Neg  Neg 
092073  Positive  Neg  192  Neg  Neg  Neg  Neg 
092089  Positive  Neg  79  Neg  Neg  Neg  Neg 
092109  Positive  Neg  316  Neg  Neg  Neg  Neg 
092110  Positive  Neg  >800  Neg  Neg  Neg  Neg 
092119  Positive  Neg  651  Neg  Neg  Neg  Neg 
092123  Positive  Neg  110  Neg  Neg  Neg  Neg 
092264  Positive  Neg  54  Neg  Neg  Neg  Neg 
092292  Positive  Neg  >800  Neg  Neg  Neg  Neg 
092325  Positive  Neg  >200  Neg  Neg  Neg  Neg 
092328  Positive  Neg  160  Neg  Neg  Neg  Neg 
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Sample  Screening  Confirmations (results in ng/mL) 
Sample ID  AMP  MAMP  AMP  MDA  MAMP  MDMA  MDEA 
092339  Positive  Neg  548  Neg  Neg  Neg  Neg 
092350  Positive  Neg  38  Neg  Neg  Neg  Neg 
096563  Positive  Neg  779  Neg  Neg  Neg  Neg 
097494  Positive  Neg  250  Neg  Neg  Neg  Neg 
097573  Positive  Neg  >200  Neg  Neg  Neg  Neg 
098102  Positive  Neg  62  Neg  Neg  Neg  Neg 
098695  Positive  Neg  78  Neg  Neg  Neg  Neg 
099260  Positive  Neg  78  Neg  Neg  Neg  Neg 
099376  Positive  Neg  >200  Neg  Neg  Neg  Neg 
099382  Positive  Neg  >200  Neg  Neg  Neg  Neg 
CW028  Positive  Neg  Positive  Neg  Inconclusive 
Neg 
Neg  Neg 
CW078  Positive  Neg  Neg  Neg  Neg  Neg  Neg 
CW090  Positive  Neg  Inconclusive  Inconclusive  Inconclusive  Inconclusive  Inconclusive 
CW144  Positive  Neg  Neg  Neg  Neg  Neg  Neg 
CW147  Positive  Positive  >200  Neg  Neg  Neg  Neg 
CW157  Positive  Neg  Neg  Neg  Neg  Neg  Neg 
CW176  Positive  Positive  >200  Neg  Neg  Neg  Neg 
CW179  Positive  Neg  73  Neg  Neg  Neg  Neg 
CW184  Positive  Neg  Neg  Neg  Neg  Neg  Neg 
CW221  Positive  Neg  Neg  Neg  Neg  Neg  Neg 
 
2.4.7.2  Unconfirmed Samples 
Approximately 250 other oral fluid samples were screened for amphetamines during 
this project but due to sample volume limitations and instrumentation problems there 
was not enough sample left to confirm. Some problems with the instrument meant 
that some batches of samples failed due to poor chromatography and low sample 
areas. Consequently, there was insufficient sample left for a repeat analysis. There 
was only a limited sample provided as many of the samples had previously been 
analysed by another laboratory. Samples collected for analysis in Forensic Medicine Page 52 
and Science were part of a drug treatment program and were frequently analysed for 
other drug groups, thus being insufficient in volume for amphetamine analysis. 
 
2.4.8  Sensitivity and Specificity 
2.4.8.1  Amphetamine and MDA 
This assay screened for amphetamine and MDA so the following calculations apply 
to these drugs as a group and not individually. There were 29 true positives, 11* true 
negatives, 6 false positives and no* false negatives for the amphetamine assay.  
*Three samples confirmed positive but screened negative as they were below the 
screening method cut-off and were thus deemed to be true negatives and not false 
negatives.  
Following the calculation given in section 2.3.6 the sensitivity of the amphetamine 
assay was calculated as 100% and the specificity was calculated as 65%. 
 
2.4.8.2  Methamphetamine, MDMA and MDEA 
This assay screened for methamphetamine, MDMA and MDEA so the following 
calculations would normally apply to these drugs as a group and not individually. 
However, in this case, as there were no positives for any of the drugs, the calculation 
does hold true for each drug individually. There were no true positives, 44 true 
negatives, 2 false positives and no false negatives for the methamphetamine assay.  
Following the calculation given in section 2.3.6 the sensitivity of the 
methamphetamine assay was unable to be calculated as there were no positive 
confirmations and the specificity was calculated as 96%. 
 
2.4.9  Case Sample Conclusions 
Most of the confirmation results matched up with the screening results for the 48 
confirmation tests carried out. However, there were a few discrepancies. Inevitably, 
some of these are false positives which are to be expected, but there were a few 
￿false negatives￿ which is worrying. Admittedly, the ￿false negatives￿, when 
confirmed gave results below the lowest standard and after taking the dilution factor Page 53 
into account (only 0.25mL of sample was available for analysis), the results were 
below the in-house ELISA cut-off concentration and were therefore correctly marked 
as negative by ELISA. The amphetamine assay was found to be very sensitive and 
correctly detected 100% of the positive samples. Both assays of interest had high 
specificity of 65% and 96% for amphetamines and methamphetamines respectively, 
which shows both assays were good at eliminating negative results from 
confirmation tests.  
Overall the amphetamine and methamphetamine ELISA assays work well and the 
controls prepared in-house are stable over time. This method can be used as an 
effective screening tool in a routine toxicology laboratory as only samples which 
confirmed as below the screening cut-off concentration were falsely screened as 
negative. However, some further work on the sensitivity of the assay at low 
concentrations would be recommended to ensure complete confidence in the 
assays. 
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3  Alcohol Enzymatic Analysis 
3.1  Materials and Reagents 
3.1.1  Immunalysis Corporation (Pomona, CA) Oral Fluid Alcohol Kit 
An alcohol oral fluid kit (502-0500, Lot No: EK4354) containing reagent A (Tris buffer 
with 0.1% sodium azide as a preservative), reagent E (containing ADH and NAD in 
Tris buffer with stabilizers and 0.1% sodium azide as a preservative) and Quantisal 
extraction buffer (product code: EXTBUF-1000) along with blank 96 well plates were 
manufactured by Immunalysis Corporation (Pomona, CA) and purchased from 
Agriyork 400 Ltd (Pocklington, UK), their UK based distributor. The kits were stored 
at or below 8￿C in the refrigerator. The specification for the assay is given in 
Appendix 5 ￿ Alcohol Assay Specification. 
 
3.1.2  Ethanol Standards 
3.1.2.1  Calibrators 
Ethanol certified reference standards in 1.2mL of water at the concentrations 
detailed in Table 17, were manufactured by Cerilliant (Round Rock, TX), and 
purchased from their UK based distributor, LGC Standards (Teddington, UK). The 
standards were stored at or below 8￿C in the refrigerator. The same calibrators were 
used for the screening and confirmation methods.  
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Table 17: Product Codes for Ethanol Calibrators 
Calibrator Concentration (mg/dL)  Product Code 
10  E-040 
25  E-035 
50  E-029 
80  E-030 
100  E-031 
200  E-032 
300  E-033 
400  E-036 
 
  
3.1.2.2  Controls 
Ethanol controls in 1.1mL of water at the concentrations detailed in Table 18, were 
manufactured by Medidrug (Kent, UK) and purchased from LGC Standards 
(Teddington, UK), their UK based distributor. The controls were stored at or below 
8￿C in the refrigerator. The same controls were used for both the screening and 
confirmations. 
 
Table 18: Product Codes for Alcohol Controls 
Control Concentration (mg/dL)  Product Code 
30  20030 
80  20080 
300  20300 
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3.1.3  Reagents 
1-propanol (HPLC grade, Part No: 29328-8) was purchased Sigma Aldrich (Dorset, 
UK). 
 
3.1.4  Materials 
Samples were diluted in 20mL headspace vials (part number 20CV-125) purchased 
from Kinesis (Cambridgeshire, UK) and capped using crimp caps (part number 
CRC20-04) that were also purchased from Kinesis (Cambridgeshire, UK).  
 
3.1.5  Collection of Neat Oral Fluid 
Neat oral fluid was collected from a single donor (who had not consumed alcohol 
within 24 hours of sample collection) by expectoration to allow greater flexibility at a 
later stage to dilute the samples to match the dilution factor of the collection device. 
Oral fluid was expectorated into a beaker and transferred to a storage bottle at the 
end of the collection period. This bottle was then stored in the freezer until required.  
 
3.1.6  Preparation of Calibrators 
The blank or alcohol free calibrator was prepared by adding 1.2mL of deionised 
water to a small vial and adding 3.6mL of the Quantisal extraction buffer. The 
positive calibrators were prepared by adding 1.2mL of the respective controls 
supplied by LGC Standards (Teddington, UK) (10, 25, 50, 80, 100, 200, 300 and 
400mg/dL) to the appropriately labelled vials and adding 3.6mL of Quantisal 
extraction buffer to each vial. The calibrators were then vortex mixed to ensure they 
were thoroughly mixed. The calibrators were stored in a refrigerator at or below 8￿C 
until required.  
 
3.1.7  Preparation of Controls 
The cut-off value for the oral fluid alcohol assay was set at 25mg/dL. A blank control 
was prepared using neat oral fluid that was collected from a donor who had not 
consumed alcohol within 24 hours of sample collection. Positive controls were Page 57 
prepared at 50% below and 50% above the cut-off value (i.e. 12.5 and 37.5mg/dL 
respectively). Two vials (1.1mL each) of 300mg/dL alcohol control (Medidrug) were 
added to a small vial. This was followed by 4.4mL of water to dilute the solution to 
100mg/dL. The solution was vortex mixed. To prepare the 50% below and 50% 
above controls, 1.25mL and 3.75mL of the 100mg/dL alcohol solution was added to 
the appropriately labelled 10mL volumetric flasks and made up to the mark with 
blank oral fluid. The solutions were inverted several times to ensure the solution was 
thoroughly mixed then transferred to a storage bottle and 30mL of Quantisal buffer 
was added to each control to match the dilution of the calibrators and samples. The 
controls were stored in a refrigerator at or below 8￿C until required.  
 
3.1.8  Preparation of Alcohol Internal Standard (1-propanol) 
The alcohol internal standard was prepared by adding 1-propanol (0.33mL) to a 1L 
volumetric flask and making up to the mark with de-ionised water to give a 
concentration of 150mg/dL. The solution was inverted several times to ensure it was 
thoroughly mixed and transferred to a labelled bottle and stored at room 
temperature. 
 
3.1.9  Equipment 
Plates were read using a MRX microplate reader using a 340nm filter which was 
purchased from Dynex Technologies. Revelation software (version 4.25) was used 
to control the MRX microplate reader and read the absorbance of the samples. 
The pipettes used in this project were calibrated by the United Kingdom 
Accreditation Service (UKAS) to ISO/IEC 17025 standard. Standards were prepared 
in volumetric flasks provided by Fisherbrand (Leicestershire, UK). 
The dilutions for the alcohol confirmations were carried out using a Compudil 300 
dilutor which was purchased from Hood & Tucker (Surrey, UK). 
Alcohol confirmations were carried out on two GC-FIDs. Both instruments were fitted 
with ThermoQuest Trace GC 2000 series gas chromatographs purchased from 
Thermo Scientific (Hertfordshire, UK). The instruments were fitted with different auto-
samplers, one used a ThermoQuest HS 2000 auto-sampler and the other used a Page 58 
ThermoQuest HS 850 auto-sampler. Both auto-samplers were purchased from 
Thermo Scientific (Hertfordshire, UK). ChromQuest software (version 2.53) was used 
on both instruments and was purchased from Thermo Scientific (Hertfordshire, UK). 
The gas chromatographs were fitted with a RXT-1 (30m x 0.25mm x 0.25￿m) and a 
RXT-2 (30m x 0.25mm x 0.25￿m) GC column purchased from Thames Restek 
(Buckinghamshire, UK). 
 
3.1.10 Case Samples 
Case samples for this project were provided from a single source. Quantum 
Diagnostics (Essex, UK) provided approximately 100 samples for this project. 
 
3.2  Methods 
3.2.1  Manufacturer￿s Instructions for Alcohol Enzymatic Assay 
The procedure used in this project was an adapted version of the method 
recommended by the manufacturer (Immunalysis Corporation (Pomona, CA) 
Corporation Catalog Number 502-0500, Version 6/2006), who recommend the use of 
a five point calibration at 0, 20, 40, 80 and 160mg/dL. To allow this method to follow 
the in-house ELISA method for drugs of abuse, it was decided to use a four point 
calibration including a blank.  A flowchart detailing the steps in this procedure is 
shown in Figure 17. 
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Allow all materials and 
reagents to come to 
room temperature 
  Record the temperature of 
the room. 
  Label appropriate 
number of strips for the 
analysis. 
       
 
Add 100￿L of reagent 
E to each well. 
 
Add 100￿L of reagent A to 
each well. 
  Pipette 10￿L of each 
calibrator, QC and 
sample into wells in 
duplicate. 
 
       
Incubate plates at 
room temperature in 
the dark for fifteen 
minutes. 
  While incubating, prepare 
plate reader by creating 
sample ID list. 
  Read plates at 340nm 
using the reader. Print 
and save results. 
       
 
        Process results. 
         
Figure 17: Method for Alcohol Screening 
 
3.2.2  Method for Alcohol Confirmations 
The Compudil dilutor was used to pipette 200￿L of calibrator, QC or sample into 
labelled vials with 500￿L of internal standard. Each sample was analysed in 
duplicate.  The vials were then crimped and loaded into the auto-sampler tray for 
analysis.  
 
3.2.3  GC-FID Conditions 
Both instruments were programmed with the same method. The auto-sampler placed 
the sample in the incubation block to heat the sample vial to 60
oC for four minutes. 
The syringe, heated to 60
oC, injected 1mL of the headspace into the GC. The GC 
was maintained at 60
oC throughout the run.  
 Page 60 
3.3  Experimental Section 
3.3.1  Response of Calibrators (Linearity) 
To evaluate the linearity of the alcohol assay, an initial calibration was prepared (i.e. 
diluted one in four with Quantisal buffer to match sample dilution) and processed at 
concentrations of 25, 80, 100, 200, 300 and 400md/dL. Subsequent analyses made 
use of a four point calibration at concentrations of 0, 25, 80 and 300mg/dL. A four 
point calibration was chosen over the full calibration to keep running costs down and 
because the method was only being used semi-quantitatively to eliminate negative 
samples from further analysis. The linearity evaluation was repeated using a full 
calibration (0, 10, 25, 50, 80, 100, 200, 300 and 400mg/dL).  
 
3.3.2  Limit of Detection 
To determine the limit of detection of the assay, 12 replicates of the blank control 
were run in duplicate on one plate. The mean and standard deviation for these 
samples were calculated and the mean plus two times the standard deviation was 
determined to be the limit of detection.  
 
3.3.3  Precision 
Two sets of plates were run, each with two different sets of calibrators and controls, 
on the same day. The seven data points gathered were used to calculate the intra-
day precision. Twenty-one controls were analysed over twelve runs, each with a set 
of calibrators and controls, on different days and this data was used to calculate the 
inter-day precision.  
 
3.3.4  Preparation of QC Charts 
To allow the preparation of a Shewart style QC chart, six batches over six different 
days were run with a set of calibrators and a set of controls. A set of controls for the 
oral fluid alcohol enzymatic assay is defined as a blank control, a control at 50% 
below the cut-off level and a control at 50% above the cut-off level. The result for the 
first positive calibrator (in this instance 25mg/dL) was chosen as the cut-off value for Page 61 
the assay. A QC chart was constructed after six replicates of the controls had been 
run. Subsequent data points were plotted on this chart to monitor the stability of the 
controls over time.  
QC charts were constructed for the cut-off value and the controls at 50% above and 
50% below the cut-off value. As all samples are analysed in duplicate, the variation 
between these results was monitored and any outlying points could be disregarded. 
The acceptable level of variation between the calibrators was 15% and between 
samples was 20%.  
 
3.3.5  Stability of Calibrators 
As ethanol is a volatile substance, it was decided to evaluate the stability of the 
controls over a two week period to determine if any ethanol was lost when the 
calibrators were stored in screw cap reagent bottles in the refrigerator. The 
absorbance of each of the calibrators was recorded and plotted on one graph to 
show any changes. Analyses were carried out on the day of preparation and on 
seven other occasions over the fourteen day period.  
 
3.3.6  Stability of Alcohol Controls in Oral Fluid 
The stability of oral fluid samples spiked with alcohol at 40mg/dL was examined over 
a fourteen day period. Spiked oral fluid was prepared by adding 0.5mL of 400mg/dL 
alcohol standard to a 5mL volumetric flask and making up to the mark with neat oral 
fluid. This solution was transferred to a 20mL volumetric flask and made up to the 
mark with Quantisal buffer. 1mL aliquots of this solution were pipetted into small 
storage vials with half being stored in the refrigerator below 8￿C and the other half 
stored in a cupboard at room temperature (typically 16 - 21￿C). Two vials from each 
set of storage conditions were analysed on six separate days. Samples were 
analysed on the day of preparation and on five further occasions over the two week 
period.  
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3.3.7  Sensitivity and Specificity 
The sensitivity and specificity of the Immunalysis ethyl alcohol assay was determined 
by calculating the sensitivity and specificity as described in section 2.3.6. 
 
3.4  Results and Discussion 
Some of the work for this project was done using reagents that had past their expiry 
date. This meant that reagent E was darker than normal. It was, however, not a 
significant problem for the assay as a calibration was run with each batch and 
therefore any effect was consistent across the batch.  
 
3.4.1  Linearity 
Figure 18 illustrates the linearity of the alcohol calibration in the 0 ￿ 400mg/dL range. 
 
 
Figure 18: Example of Linearity of Full Calibration Page 63 
 
As can be seen above, the Immunalysis Corporation (Pomona, CA) alcohol oral fluid 
assay demonstrates good linearity over the 0 ￿ 400mg/dL range as evidenced by the 
R
2 value, which was above 0.99. As this method was being evaluated as a screening 
method, a full calibration was not necessary, and four points from the calibration 
above were run with all other batches.  
An example of this four point calibration is shown in Figure 19. 
 
Figure 19: Example of Alcohol Oral Fluid Linearity 
 
The Immunalysis Corporation (Pomona, CA) alcohol oral fluid assay demonstrates 
good linearity when used with a four point calibration over the 0 ￿ 300mg/dL range 
as evidenced by the R
2 value, which was above 0.99.  
 
3.4.2  Limit of Detection 
Table 19 summarises the statistical variation of twelve replicates of the blank control 
that were analysed in duplicate in a single batch.  Page 64 
 
Table 19: LOD Results 
  Mean 
Values 
Mean  0.972 
STD DEV  0.0146 
2 X STD 
DEV  0.0291 
MEAN + 
2SD  1.001 
%CV  1.50 
 
The results above show that the blank control gives reproducible results when run on 
one plate as evidenced by the coefficient of variation of 1.5%. The absorbance of the 
cut-off concentration (25mg/dL) within this batch was 1.049. The absorbance of the 
blank calibrator within this batch was 0.954. The 50% below the cut-off control, 
spiked at 12.5mg/dL, had an absorbance value of 1.035 within this batch and is also 
higher than the limit of detection thus indicating that the assay is fit for purpose. 
 
3.4.3  Precision 
Table 20 summarises the statistical data for inter and intra-day precision of the assay 
by looking at the mean absorbance values. 
 
Table 20: Intra- and Inter Day Precision 
Intra-Day Precision (n=7)  Inter-Day Precision (n=21) 
  50% Below  50% Above    50% Below  50% Above 
Mean  1.025  1.059  Mean  1.022  1.122 
Std Dev  0.021  0.018  Std Dev  0.027  0.039 
%CV  2.1  1.7  %CV  2.7  3.5 
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The precision data indicates that there is less variation between results from runs on 
the same date than there is between runs from different days. While the coefficient of 
variation for the intra-day precision is lower (<2.5%), the inter-day precision is still 
acceptable (<4%). This shows that there is good reproducibility of results on the 
same day and on different days. The 50% below the cut-off value control is quite 
close to the limit of detection for the assay.  
 
3.4.4  Stability of Calibrators 
The stability of the alcohol calibrators was monitored by plotting the absorbance 
reading versus time over a two week period. The calibrators were stored in screw 
cap bottles in a fridge between analyses. The results are shown Figure 20 . 
 
 
Figure 20: Stability of Alcohol Calibrators over a Two Week Period 
 
Figure 20 demonstrates that there is no substantial loss of alcohol from the 
calibrators over a two week period. The absorbance values seen on this chart are 
lower than the LOD for the lowest standard as a new set of reagents were used that 
were lighter in colour to a previous set that had been used to calculate the LOD data.  
 
While the calibrators are stable over time when refrigerated, the highest calibrator 
exhibited a loss of absorbance depending on how long it had been since the Page 66 
calibrator had been pipetted into the wells and reagent E was added to the wells. 
The results of a short study to investigate this effect are shown in Figure 21. 
 
 
Figure 21: Calibrator Response versus Time 
 
Figure 21 shows that although all results fall within two standard deviations of the 
mean, there is a considerable loss in absorbance reading with increasing time before 
adding the reagent. This becomes a problem if a large number of samples are being 
analysed at the same time, as the later samples will appear to have higher 
concentrations than they actually have due to this apparent loss. The problem 
however, seems to be limited to the higher concentrations of alcohol as no significant 
loss was noticed with the lower calibrators. Although a slight loss was observed for 
the 80mg/dL calibrator, (data shown in Appendix 6 ￿ Alcohol Stability Charts) in 
terms of absolute absorbance, it is not too significant and could be attributed to 
experimental uncertainty. 
 In addition, the first samples to be pipetted are the calibrators and thus if the 
absorbance of the highest calibrators falls over time then the slope of the chart will 
be lowered and consequently this method is not suitable for quantitative analysis. 
Four strips from the plate were typically used for a batch, but for the four batches 
that used the full twelve strips on the plate, the mean absorbance value for the Page 67 
300mg/dL calibrator from those batches was 1.438, which if plotted on the QC chart, 
Figure 21, would be well outside the acceptable range. This could represent a 
problem for any routine laboratory that was analysing large numbers of samples.  
 
 
3.4.5  Stability of Alcohol Controls in Oral Fluid 
The stability of oral fluid controls was evaluated for different storage conditions. 
Eppendorf vials and screw cap vials were used for the comparison with a set of each 
being evaluated while at room temperature and one set stored in a refrigerator. 
 
3.4.5.1  Eppendorf Vials 
The stability of the oral fluid samples spiked with alcohol and refrigerated in 
eppendorf vials are illustrated in Figure 22. Set 1 was only run for seven days. 
 
Figure 22: Stability of Spiked Oral Fluid Samples Stored in a Refrigerator Over Fourteen Days 
 
Figure 22 demonstrates that oral fluid samples spiked with alcohol are stable over a 
fourteen day period if stored in eppendorf vials in a refrigerator at or below 8￿C. The 
variation between the results is due to experimental error and not due to a loss of 
any sample thus it can be deduced that storing samples in eppendorf vials in a Page 68 
refrigerator is a suitable way to store alcohol positive oral fluid samples in the short-
term. 
The stability of the oral fluid samples spiked with alcohol and stored at room 
temperature in eppendorf vials are illustrated in Figure 23. Set 1 was only run for 
seven days. 
 
 
Figure 23: Stability of Spiked Oral Fluid Samples Stored at Room Temperature Over Fourteen Days 
 
Figure 23 highlights that alcohol is not stable in oral fluid samples stored in 
eppendorf vials over a fourteen-day period if stored in the dark at room temperature. 
Given that these samples came from the same solution as those that were stored in 
the refrigerator over the same fourteen-day period and exhibited no loss of alcohol, it 
can be assumed that the most likely reason for the loss of alcohol from these 
samples is due to the storage conditions, in particular the temperature at which they 
were stored. The rate of decrease in alcohol concentration is high enough to warrant 
concern for samples that are transported overnight or perhaps for a longer period of 
time in non-refrigerated conditions. This is however, only a screening method and 
these findings would need to be confirmed by headspace gas chromatography ￿ 
flame ionisation detector (GC-FID). 
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3.4.5.2  Screw Cap Vials 
Figure 24 and Figure 25 below summarise the data generated for alcohol spiked oral 
fluid samples stored in screw cap vials over a fourteen day period when refrigerated 
and at room temperature respectively. 
 
Figure 24: Stability of Spiked Oral Fluid Samples Stored in the Fridge Over Fourteen Days 
 
 
Figure 25: Stability of Spiked Oral Fluid Samples Stored at Room Temperature Over Fourteen Days 
 
Figure 24 andFigure 25 demonstrate that there is no loss of alcohol from screw cap 
vials when either stored at room temperature or refrigerated. This indicates that 
screw cap vials are a more suitable storage medium for alcohol containing oral fluid Page 70 
samples than eppendorf vials and that they should be used for the storage of 
controls.  
3.4.6  QC Charts 
QC charts were constructed for the cut-off value (Figure 26), the 50% below the cut-
off control (Figure 27) and the 50% above the cut-off control (Figure 28).  
 
Figure 26: Alcohol Control Chart Cut-off Value 
 
 
Figure 27: Alcohol Control Chart 50% Below Cut-off 
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Figure 28: Alcohol Control Chart 50% Above Cut-off 
 
Figure 26 ￿ Figure 28 above highlight the problem with Shewart-style QC charts for 
this analysis. They demonstrate that the controls give fairly sporadic results as there 
are a number of factors that influence the absorbance. There is a general upwards 
trend in each of the above charts as reagent E gets closer to its expiry date. The 
azide preservative in the solution gives the solution its colour and gets darker as the 
solution approaches its expiry date. The reagent has a short shelf life, only a couple 
of months, and slight changes can be observed in the QC charts over time 
  
3.5  Case Samples 
3.5.1  Confirmed Samples 
A number of samples (both positive and negative screening results) were confirmed 
by headspace GC-FID for the presence of alcohol. The results are detailed in the 
Table 21. 
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Table 21: Confirmation Results for Alcohol Samples 
Sample Details  Alcohol Results 
Sample ID  Screening  Confirmation 
015070  Neg  Neg 
027660  Neg  Neg 
027713  Neg  Neg 
041616  Positive  Neg 
041669  Neg  Neg 
041676  Neg  Neg 
042532  Neg  Neg 
043746  Neg  Neg 
043839  Neg  Neg 
043881  Neg  Neg 
043914  Neg  Neg 
044102  Positive  23 
044116  Neg  Neg 
044194  Positive  314 
055625  Positive  180 
057429  Borderline  Neg 
089931  Neg  Neg 
092020  Neg  Neg 
092045  Neg  Neg 
092055  Positive  12 
092073  Neg  Neg 
092089  Positive  20 
092108  Positive  Neg Page 73 
Sample Details  Alcohol Results 
Sample ID  Screening  Confirmation 
092109  Neg  Neg 
092110  Neg  Neg 
092113  Neg  Neg 
092119  Positive  Neg 
092123  Borderline  Neg 
092264  Neg  Neg 
092290  Positive  22 
092292  Neg  Neg 
092302  Borderline  11 
092325  Neg  Neg 
092328  Neg  Neg 
092336  Neg  Neg 
092339  Neg  Neg 
092350  Neg  Neg 
096563  Borderline  Neg 
097494  Neg  Neg 
097573  Neg  Neg 
098102  Neg  Neg 
099249  Positive  31 
099260  Neg  Neg 
099376  Neg  Neg 
099382  Neg  Neg 
   Page 74 
The confirmation results generally match the screening results and there were no 
false negatives from the samples that were confirmed. This is somewhat surprising 
as there is not a large difference between the blank and cut-off calibrators 
absorbance values so more false negatives would have been expected. These 
results indicate that the assay would be useful as a screening technique for alcohol 
screening. 
 
3.5.2  Unconfirmed Samples 
Approximately fifty other oral fluid samples were screened as part of this project but 
due to the limited sample volumes obtained by oral fluid collection devices there was 
not enough left for confirmations as the samples had previously been analysed by 
another laboratory.  
 
3.5.3  Sensitivity and Specificity 
There were 8 true positives, 31 true negatives, 6 false positives and no false 
negatives for the alcohol assay.  
NB: For the purposes of this calculation, borderline cases were treated as being 
positives. 
Following the calculation given in section 2.3.6 the sensitivity of the alcohol assay 
was calculated as 100% and the specificity was calculated as 84%. 
 
3.6  Conclusions 
The Immunalysis Ethyl Alcohol Screening Kit has shown potential as a screening 
method but would require further work and validation before it demonstrated as fit for 
use in a routine testing laboratory. The calibrators and controls have shown short 
term stability over a two week period, which is the likely time frame for sample 
analysis in a high throughput routine testing laboratory.  
A more suitable method of evaluating the performance of the control samples would 
need to be devised and evaluated as the current QC charts are unsuitable for a Page 75 
small  laboratory who would not use all of the reagent in one or two days and would 
therefore limit the assay￿s use to high throughput laboratories.  
The assay consistently produced a linear response for the calibration range tested 
and as such has potential as a semi-quantitative test, which would be useful for 
highlighting any samples that may require a dilution prior to analysis. However, the 
issue of the highest calibrator ￿losing￿ absorbance over time would need to be 
thoroughly investigated as this would lower the gradient of the calibration and 
samples pipetted later in the plate would appear to be of a higher concentration than 
they actually are, while earlier low concentration samples could appear negative. 
This would forfeit the point of the screening test as false negatives would be 
produced and samples requiring dilution would not be properly identified. 
If the issues outlined are successfully addressed and the analysis of test samples 
proves successful then this method could be used as a screening procedure for 
alcohol in oral fluid. The main benefits of the assay are that it is simple to use and 
provides a fast screening result. In addition, it has the potential to be used semi-
quantitatively if the issues mentioned above are resolved. However, the assay does 
have its limitations in that the sample preparation step for analysis is to pipette the 
sample into wells, which is the same as the confirmation method. So in this respect, 
the sample preparation is as time-consuming as the confirmation method and it 
would make more sense to go straight to the confirmation method even though the 
results for the screening test would be obtained within 15 minutes whereas the 
confirmation method would take several hours.  If the assay was being used in a 
setting where most samples were expected to be negative, for example in the 
workplace, then it would be a good choice.  
In a laboratory that gets many positives, such as a forensic laboratory that carries 
out alcohol testing in road traffic cases then this method is only likely to add to the 
workload and therefore could not be justified.  
Overall, the assay would not be recommend for a laboratory that is only analysing a 
small number of alcohol analyses a day as it would offer no significant advantage 
due to the issues highlighted above. In addition, it would not be recommend the for a 
high throughput laboratory analysing several hundred samples daily if they are 
expecting many positives as it would be an added expense and waste of time. It Page 76 
would however, be very useful if utilized in a laboratory analysing samples for drug 
abstinence in the workplace. 
Initial results from real samples gave promising results, but further real samples 
should be tested before this method is put to use routinely in a laboratory. 
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4  Conclusions 
The Immunalysis ELISA assays worked well with oral fluid that had been diluted one 
in four with Quantisal buffer. The Quantisal oral fluid collection device dilutes 1mL of 
sample with 3mL of buffer giving one of the largest dilutions of all commercially 
available oral fluid collectors. This raised the possibility of screening results giving 
false negatives due to the buffer diluting the sample below the cut-off concentration. 
This did not appear to be the case and means that the Quantisal oral fluid collection 
device offers the distinct advantage of having more oral fluid/buffer mixture to 
analyse than other commercially available devices.  
The Immunalysis ELISA assays for drugs of abuse that were used for this project 
proved sufficiently sensitive to detect the low drug concentrations found in the diluted 
oral fluid/buffer mixture. The assays did raise a couple of questions with very low 
amphetamine concentrations that were below the lowest calibrator. The confirmation 
results for the samples that ￿falsely￿ screened negative showed that they were below 
the ELISA assay￿s in-house cut-off limit and were therefore accurately marked as 
negative by ELISA. The Immunalysis ELISA assays are therefore suitable for use as 
a laboratory based screening technique for oral fluid samples.  
 
The alcohol enzymatic assay showed some potential as a screening technique for 
oral fluid. The assay showed good linearity and of the confirmed samples, there were 
no false negatives identified. The study did highlight some issues that would require 
further investigation before being used routinely in a toxicology laboratory. This study 
showed a worrying trend of the absorbance of the highest calibrator falling with time 
between addition to the well and addition of the other reagents. From a single 
analysis, this relationship appeared to be linear but further investigation would be 
required to confirm this relationship.  
One of the reagents appeared to get darker in colour, and thus gave different values 
for its absorbance once opened and this meant that the preferred in-house method 
of using Shewart-style QC charts was unsuitable for this analysis. No obvious 
alternative method of monitoring quality control was available and this would need to 
be rectified if the assay was to be used in a laboratory accredited to ISO/IEC 17025 
where the monitoring of quality control samples is so important. The reagent Page 78 
becoming darker was observed after one day and this could present a problem to 
small scale laboratories that are not carrying out many analyses.  
Overall, this method has the potential to be valuable to laboratories testing oral fluid 
samples where sample volume is limited and also to high throughput laboratories 
where most of the samples are expected to be negative, such as laboratories that 
carry out workplace testing.  
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5  Further Work 
Further work to evaluate the stability of the controls would be to prepare several 
litres of the controls and analyse weekly for up to five years to assess the long term 
stability of multi-analyte controls. Several batches of controls should be prepared 
simultaneously and analysed at the same time to ensure the results are 
reproducible.  
Concurrently, controls could be prepared and stored, ready diluted in Quantisal 
buffer, to allow a comparison between the stability of diluted and neat controls over 
time. Both the neat and diluted controls should be prepared on the same day with 
the same blank oral fluid and drug stock solutions and stored in the same freezer to 
minimise the differences between the controls, thus reducing the number of variable 
factors which may affect the stability. 
Another step would be to examine why some drug groups have such a wide range of 
acceptable values and others have a narrow range. Examining whether each drug￿s 
assay works better at a specific temperature and whether that is a reason for the 
more sporadic results for some drugs, could improve the reproducibility of the results 
for some assays. 
As the calibrators for ELISA used a different buffer to the oral fluid controls (to keep 
the method in line with the in-house blood and urine method), the effect of this could 
be investigated to see if there is any matrix effects from the different buffers.  
Further samples should be collected and analysed purely for amphetamines if 
possible to allow sufficient sample to be analysed and any repeats carried out. This 
would allow the questionable false negatives to be clarified and further data to be 
collected to allow for a more accurate confirmation of the borderline positive 
confirmations.  
Spiking samples at and below the lowest calibrator from the confirmation method 
would provide information about the assays suitability at low concentrations. 
The first step would be to devise a more suitable method of quality control. Once this 
is in place, the next step would be to evaluate the long term stability of the calibrators 
and controls. Longer stability would reduce the running costs of the screening test as 
certified alcohol standards are expensive. While the stability study is underway, an Page 80 
evaluation of the effect of reagent E could be undertaken by analysing two batches 
of calibrators and controls, one with a new reagent E each time and the other using a 
previously opened reagent E. My results indicated that there was a slight increase in 
the absorbance after just one day, however,  that could have been due to slight 
differences in the analysis such as a slightly longer incubation time or a change in 
laboratory temperature. The effect of these should also be investigated.  
The apparent loss of alcohol from the highest calibration over time is a serious issue 
that would also need to be fully investigated prior to being implemented in a 
laboratory. This could be done by analysing controls on one plate and leaving a set 
period of time between the additions of controls to each strip and adding reagents A 
and E once all strips have had sample added. Also, a strip of calibrators could be 
added to a plate every two minutes to see any change in absorbance when reagents 
A and E are added to all strips at the same time. 
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7  Appendices 
7.1  Appendix 1 ￿ Amphetamine Worksheet 
Worksheet for the Extraction of Amphetamines from Oral Fluid 
 
 
 
Follow the steps outlined below, noting when asked the solution or reagent numbers. Initial and date 
each step as completed and ask the witness to initial and date when prompted. 
======================================================================= 
STEP ONE: Preparation of Standard Calibrators, Samples and QC￿s (WITNESSED) 
The preparation of the following standards, samples and controls must be carried out in a fume hood 
or safety cabinet using labelled glass test-tubes. Tubes should be labelled for the standards, blank, 
spike and samples. 
  To each standard test tube add the following volumes of Amphetamines working standard 
(1￿g/mL) (SOL No.:_______). 
  50￿L of 1￿g/mL internal standard (AMP-d11, MAMP-d14, MDA-d5, MDMA-d5 and MDEA-d6) 
(SOL No.:_______) should be added to all test tubes. 
  A blank with just internal standard should also be prepared. 
  Two spikes should be prepared by adding 1mL of the positive amphetamine oral fluid QC (X2) 
(CON No.:_______) (CON No.:_______). 
  A total of 9 blanks and standards. 
Once all standards have been added, 3mL of 0.1M phosphate buffer pH 6.0 (SOL No.:_______) 
should be added, followed by 1mL of blank oral fluid (SOL No.:_______). 
  Pipette 0.5mL of each sample into the appropriately labelled test-tube and note any changes 
to the sample volume on form FMS2005/F001. 
Standard (concentration) 
Volume of 
Working Solution 
(1￿g/mL) 
Volume of Internal 
Standard 
(1￿g/mL) 
Std 1 (5ng/mL)  5￿L  50￿L 
Std 2 (10ng/mL)  10￿L  50￿L 
Std 3 (25ng/mL)  25￿L  50￿L 
Std 4 (50ng/mL)  50￿L  50￿L 
Std 5 (100ng/mL)  100￿L  50￿L 
Std 6 (200ng/mL)  200￿L  50￿L 
Blank (0ng/mL)  0￿L  50￿L 
Spike (45ng/mL)  1mL of QC  50￿L 
Note: Date of calibration used: _______________ 
  Vortex mix all standards, samples and spike then centrifuge at 2500rpm for 10 minutes. 
 
 
 
*IMPORTANT ￿ A Batch Record Form (FMS2005/F001) 
must be completed before starting the extraction process * 
Analyst: _____________ 
Date: _______________ 
Analyst/Date: ____________________   Witness/Date: ____________________ Page 86 
STEP TWO: Sample Extraction 
  Place labelled CleanScreen columns on the vacuum manifold.  
  Add 3mL of methanol (CHEM No.:_______). 
  Add 3mL of deionised water (CHEM No.:_______). 
  Add 1mL of 0.1M phosphate buffer pH 6.0 (SOL No.:_______). 
  Transfer the buffered sample to the column and allow to pass through completely 
(WITNESSED). 
 
 
 
  Add 3mL of deionised water (CHEM No.:_______). 
  Add 1mL of 1M acetic acid (SOL No.:_______). 
  Add 3mL of methanol (CHEM No.:_______). 
  Dry under full vacuum for 5 minutes. 
  Place labelled 4mL glass vials in a rack within the vacuum manifold (WITNESSED). 
 
 
 
 
  Elute with 2mL of DCM/IPA/NH3 (78:20:2 v/v/v) (SOL No.:_______). 
  Add 100￿L of tartaric acid (SOL No.:_______). 
  Evaporate to dryness under N2 at ROOM temperature. 
  Add 50￿L of PFPA:EtOAc (2:1 v/v) (SOL No.:_______). 
  Cap the vials and derivatise at 60”C for 20 minutes. 
  Evaporate to dryness under N2 at ROOM temperature. 
  Reconstitute in 50￿L of ethyl acetate (SOL No.:_______) and transfer to labelled injection 
vials with inserts. 
 
 
 
 
 
 
Analyst/Date: ____________________   Witness/Date: ____________________ 
Analyst/Date: ____________________   Witness/Date: ____________________ 
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7.2  Appendix 2 ￿ ELISA Assay Specification 
7.2.1  Immunalysis Amphetamine ELISA Specification 
 
 
 Page 88 
 
7.2.2  Immunalysis Benzodiazepine ELISA Specification 
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7.2.3  Immunalysis Cannabinoid ELISA Specification 
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7.2.4  Immunalysis Cocaine ELISA Specification 
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7.2.5  Immunalysis Methadone ELISA Specification 
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7.2.6  Immunalysis Methamphetamine ELISA Specification 
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7.2.7  Immunalysis Opiate ELISA Specification 
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7.3  Appendix 3 ￿ ELISA QC Charts  
7.3.1  Benzodiazepine Control Charts 
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7.3.2  Cannabinoid Control Charts 
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7.3.3  Cocaine Control Charts 
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7.3.4  Methadone Control Charts 
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7.3.5  Opiate Control Charts 
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7.4  Appendix 4 ￿ Confirmation QC Charts 
7.4.1  Methamphetamine Control Chart 
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7.4.2  MDA Control Chart 
 
 
7.4.3  MDMA Control Chart 
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7.4.4  MDEA Control Chart 
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7.5  Appendix 5 ￿ Alcohol Assay Specification 
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7.6  Appendix 6 ￿ Alcohol Stability Charts 
7.6.1  0mg/dL Calibrator 
 
 
7.6.2  25mg/dL Calibrator 
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7.6.3  80mg/dL Calibrator 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 